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Tuberculosis (TB) is the leading cause of death in individuals infected with human 
immunodeficiency virus (HIV) in several African countries, including South Africa. HIV-positive 
individuals do not have the immune system resources to keep TB in check and are as much as 30 
times more likely to develop active TB than people who are HIV-negative. Many people infected 
with HIV develop TB as the first manifestation of AIDS and TB accelerates disease progression 
in HIV-positive individuals. HIV and TB pathogenesis are thus inextricably intertwined so that it 
is necessary for medical practitioners to have an understanding of the dynamics and treatment of 
HIV-TB coinfection. At present the question remains as to whether the best time for coinfected 
individuals to start antiretroviral treatment for HIV is at the beginning, the peak, or after the 
completion of the TB treatment phase. This dissertation was undertaken with the aim of obtaining 
some clarity on this question by creating a mathematical model of HIV-TB coinfection and its 
treatment. This needs an understanding of the biological interactions; therefore the dissertation 
begins with a discussion of the biological mechanisms of HIV, the human immune system, TB 
and the drug therapies for each disease. Thereafter a brief introduction to mathematical modelling 
reviews basic HIV models, which are then modified to include HIV drug therapy. Analyses and 
simulations of these models were carried out, which yielded some insights into the dynamics of 
HIV and HIV therapy. Finally HIV-TB coinfection is introduced by reviewing a previously 
developed model. Based on all the models reviewed, a model for coinfection is developed which 
includes treatment for HIV and TB. Numerical simulations suggest that, if HIV disease 
progression is at an advanced stage of the immune system collapsing towards AIDS, with low       
T-cell count and high viral load, it is necessary to treat for both diseases simultaneously to ensure 
a positive survival prognosis for the coinfected individual. However, if disease progression is in 
the early stages of AIDS, with T-cell count and viral load beginning to display signs of the 
immune system collapse but still at reasonable levels relative to advanced stages, it need not be 
necessary to treat both diseases simultaneously. TB can be treated first, and upon completion HIV 
treatment can be initiated thus sparing the coinfected individual from the compounded side-






I would like to express my sincere gratitude to my supervisor, Dr. A.P. Matthews, and 
cosupervisor, Dr. H.G. Mwambi. They have allowed me the academic freedom to choose 
the path that my research should take and were always willing to offer their knowledge 
and guidance. I would also like to express my gratitude to my parents, Anand and 







This dissertation represents the original work of the author. In the instances where use has 
been made of other researchers’ work, acknowledgements are duly made. This research 






4 October 2007 







2 November 2007 









2 November 2007 










To all those who have been affected by HIV/AIDS, directly or indirectly. By facing such 
adversity we are constantly reminded of the great resilience of the human spirit. Due to 
the disease one witnesses firsthand the amazing capacity for human compassion of those 
people who are involved in the fight against HIV/AIDS. Many people all over the world 
are united in selflessly pooling their resources – be they financial, academic or social – to 








1. Introduction ................................................................................................................... 1 
 
2. Human Immunodeficiency Virus ................................................................................ 5 
2.1. Basic Virology .......................................................................................................... 5 
2.2. HIV: An Overview .................................................................................................... 6 
2.3. HIV Virion Structure ................................................................................................ 6 
2.4. HIV Replication Cycle .............................................................................................. 8 
2.4.1. Virion Binding and Capsid Insertion .................................................................. 8 
2.4.2. Reverse Transcription and Integration ................................................................ 8 
2.4.3. Transcription and Translation ............................................................................. 9 
2.4.4. Assembly, Budding and Maturation ................................................................... 9 
2.5. HIV Disease Progression ........................................................................................ 10 
2.5.1. Primary Infection .............................................................................................. 11 
2.5.2. Asymptomatic Infection .................................................................................... 12 
2.5.3. Symptomatic Infection ...................................................................................... 12 
2.5.4. AIDS ................................................................................................................. 12 
2.6. HIV/AIDS Drugs and Treatment Strategies ........................................................... 13 
2.7. Viral Mutations and Drug Resistance ..................................................................... 14 
2.8. Origin of HIV .......................................................................................................... 15 
2.9. History of HIV ........................................................................................................ 16 
 
3. Human Immune System ............................................................................................. 18 
3.1. Immune System: An Overview ............................................................................... 18 
3.2. Immune System Cells ............................................................................................. 19 
3.2.1. B cells ................................................................................................................ 19 
3.2.2. T cells ................................................................................................................ 20 
3.2.2.1. CD8
+
 T cells ................................................................................................ 21 
3.2.2.2. CD4
+
 T cells ................................................................................................ 21 
3.2.3. Macrophages ..................................................................................................... 22 
 
4. Tuberculosis ................................................................................................................ 23 
4.1. Tuberculosis: An Overview .................................................................................... 23 
4.2. Tuberculosis Epidemiology .................................................................................... 24 
4.3. Tuberculosis-HIV Coinfection ................................................................................ 24 
4.4. Tuberculosis Pathogenesis ...................................................................................... 25 
4.5. Tuberculosis Treatment .......................................................................................... 26 
4.5.1. Antituberculosis Drugs ..................................................................................... 27 
4.5.1.1. Rifampicin ................................................................................................... 27 
4.5.1.2. Ethambutol .................................................................................................. 28 
4.5.1.3. Isoniaziad .................................................................................................... 28 




5. Mathematical Biology ................................................................................................. 30 
5.1. Population Models .................................................................................................. 31 
5.1.1. Fibonacci Sequence .......................................................................................... 32 
5.1.2. Predator-Prey Model ......................................................................................... 33 
5.1.2.1. Lotka-Volterra Equations ............................................................................ 33 
Mathematical Analysis .......................................................................................... 35 
Computational Analysis ........................................................................................ 37 
 
6. HIV-Immune System Models .................................................................................... 41 
6.1. Basic HIV-Immune System Model ......................................................................... 41 
6.1.1. Conditions for Infection .................................................................................... 42 
6.1.2. Simulations ....................................................................................................... 44 
6.1.3. Analysis and Implications ................................................................................. 46 
6.2. Basic HIV Model with Treatment ........................................................................... 47 
6.3. Late versus Early Treatment ................................................................................... 49 
6.3.1. Model Development .......................................................................................... 50 
6.3.2. Model Simulation .............................................................................................. 53 
6.3.3. Bifurcation Analysis ......................................................................................... 55 
6.3.4. Finding R0 ......................................................................................................... 59 
6.3.5. Model with AZT Monotherapy ......................................................................... 61 
 
7. HIV-TB Coinfection Model ........................................................................................ 65 
7.1. Model Development ................................................................................................ 65 
7.2. Simulations ............................................................................................................. 69 
7.2.1. Uninfected Steady-State .................................................................................... 69 
7.2.2. HIV Infected Steady-State ................................................................................ 70 
7.2.3. TB Infected Steady-State .................................................................................. 71 
7.2.4. Coinfected Steady-State .................................................................................... 71 
 
8. Modelling Coinfection Treatment ............................................................................. 73 
8.1. Model Development ................................................................................................ 74 
8.2. Model Simulations .................................................................................................. 77 
8.2.1. Primary and Asymptomatic HIV Infection ....................................................... 77 
8.2.2. Complete Course of HIV Infection ................................................................... 78 
8.2.3. HIV-TB Coinfection ......................................................................................... 80 
8.3. Modelling Treatment .............................................................................................. 81 
8.3.1. Simultaneous HIV-TB Treatment ..................................................................... 84 
8.3.2. Treating TB then HIV: Advanced Stages of Immune Collapse ....................... 86 
8.3.3. Treating TB then HIV: Early Stages of Immune Collapse ............................... 88 
8.3.4. Treating HIV then TB ....................................................................................... 90 
 
9. Conclusion ................................................................................................................... 92 
 
References ........................................................................................................................ 95 
 
 viii 
Table of Figures 
 
 
1. Structure of HIV virion ................................................................................................... 7 
 
2. Electron microscope image of HIV virion budding ...................................................... 10 
 
3. Graph of generalised HIV disease progression ............................................................. 11 
 
4. Electron microscope image of M. tuberculosis ............................................................. 23 
 
5. Flowchart of mathematical model development ........................................................... 31 
 
6. Fibonacci sequence growth curve of rabbit population ................................................ 33 
 
7. Qualitative plots (slope field and phase portrait) 
    of the Lotka-Volterra system ........................................................................................ 37 
 
8. Simulations of the Lotka-Volterra system .................................................................... 38 
 
9. Solutions of Lotka-Volterra system superimposed ....................................................... 38 
 
10. Ecological data of lynx-hare predator-prey system .................................................... 39 
 
11. Schematic diagram of the basic HIV immune system model ..................................... 42 
 
12. Schematic diagram of the initial proliferation process of HIV virions ....................... 43 
 
13. Simulations of the basic HIV model for two regimes of 0R  values: 
      10R  and 10R  ....................................................................................................... 45 
 
14. Schematic diagram of the Kirschner-Webb model ..................................................... 53 
 
15. Simulations of the Kirschner-Webb model for three different 
      regimes of the external viral source values: Vg =5, 20, 
      and increasing Vg  from 5 to 20 over time  ................................................................. 54 
 
16. Bifurcation diagram of Kirschner-Webb model created by varying 
      Vg  from 5 to 20 .......................................................................................................... 57 
 
17. Two parameter bifurcation diagram for Kirschner-Webb model 
      with growth rate of external viral source Vg  vs. number of virions 
      produced from cell bursting N  .................................................................................. 58 
 
 ix 
18. Bifurcation diagram of Kirschner-Webb model created by varying 
      Vg  from 0 to 5 ............................................................................................................ 61 
 
19. Simulations of Kirschner-Webb model for early continuous 
      and late continuous AZT monotherapy treatment ...................................................... 63 
 
20. T cell counts for early and late treatment regimes superimposed ............................... 64 
 
21. Simulations of the uninfected state for the Kirschner coinfection model ................... 69 
 
22. Simulations of the HIV infected state for the Kirschner coinfection model ............... 70 
 
23. Simulations of the TB infected state for the Kirschner coinfection model ................. 71 
 
24. Simulations of the HIV-TB coinfected state for the Kirschner 
      coinfection model ........................................................................................................ 72 
 
25. Simulations of the primary and asymptomatic stage of HIV infection 
      for new model ............................................................................................................. 77 
 
26. Simulations of the complete course of HIV infection for new model ........................ 79 
 
27. Simulations of the HIV-TB coinfection for new model ............................................. 80 
 
28. Simulations of the simultaneous treatment of HIV and TB for new model ............... 85 
 
29. Simulation of premature cessation of TB treatment for new model ........................... 86 
 
30. Simulations of treating TB then HIV at advanced stages of immune system   
      collapse for new model ............................................................................................... 87 
 
31. Simulations of treating TB then HIV at early stages of immune system   
      collapse for new model ............................................................................................... 89 
 








HIV/AIDS represents a multifaceted challenge to society. Its burden is felt not only by 
the mortality rates associated with the disease, but also in terms of its social and 
economic impact. In order for humanity to come to terms with this scourge, there needs 
to be collaboration by the different groups of people who are involved in the fight against 
the disease. This need is most apparent in the scientific sphere. As an example the 
collaboration of mathematical and biological scientists has proved successful in revealing 
features of viral dynamics that were previously unknown. Mathematical models have 
been used to demonstrate the somewhat counter-intuitive fact that during the 
asymptomatic stage of HIV disease progression the viral turnover rate is approximately 
10 billion HIV virions per day.  
 
Such successes clearly encourage the development of mathematical models to yield 
insight into the quantitative and qualitative dynamics of disease progression. An area 
where this insight could potentially be useful is the problem of HIV-TB coinfection. Sub-
Saharan Africa in particular has very high HIV-TB coinfection rates. TB is curable in 
HIV-positive individuals. In fact, if TB is not treated, the HIV disease progression 
increases in its rapidity and death soon results. Generally, when people are HIV-TB      
coinfected, their immune system is already well on its way to collapsing towards AIDS. 
This means that the immune system is in a delicate state; therefore, death could result 
from either one of the two diseases. Even so, medical practitioners are reluctant to treat 
both diseases simultaneously due to the adverse compounded side-effects and undesirable 
drug-drug interactions of combining HIV and TB treatment. This problem is significant 
enough to warrant the running of medical trials in order to answer the question, when 
would the optimal point in time be to commence antiretroviral treatment in coinfected 
individuals? The START trials (STarting Anti-Retroviral Therapy) undertaken by the 
Centre for the AIDS Programme of Research in South Africa (CAPRISA) in order to                          
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address the issues involving treatment of coinfection seek to ascertain whether the best 
time to start antiretroviral treatment for HIV-TB coinfected individuals is at the 
beginning, the peak, or after the completion of the TB treatment phase. 
 
The main aim of the dissertation focuses on this HIV-TB treatment predicament. One 
might sense that the development of a mathematical model to simulate the treatment of 
HIV-TB coinfection could lead to some practical insight as to what the best strategy to 
treat for coinfection is likely to be. Since medical trials such as START are typically time 
intensive, a mathematical model could offer predictions to medical researchers while they 
wait for the trials to run its course. Furthermore, once the trials are completed, the model 
can be evaluated using the clinical data from the trials. Thus the central goal in 
undertaking this research was to develop a mathematical model to simulate the treatment 
of HIV-TB coinfection and to test the various strategies used to treat coinfection. By 
doing this one is able to offer some suggestions, in terms of the model’s results, as to 
what the optimal method of treating for coinfection is likely to be.  
 
One should bear in mind that building and testing such a model requires an 
interdisciplinary approach. One needs firstly to be familiar with the biological aspects of 
the dynamics. Thereafter one needs to translate these biological dynamics into 
mathematical formalism by way of equations, which are then solved computationally in 
many cases. For this reason the contents of this dissertation can be viewed as having two 
distinct, but equally important, parts. The first part, Chapters 2 to 4, is devoted to 
describing the biological underpinnings of Human Immunodeficiency Virus (HIV), 
Tuberculosis (TB), the human immune system and the treatment therapies for HIV and 
TB. The second part, Chapters 5 to 8, deals with the mathematical modelling component 
of the research. 
 
An introduction to the biological aspects of HIV-TB coinfection and its treatment was 
undertaken to familiarise the reader with the mechanisms of biological interactions of the 
system to be modelled. However, in attempting to understand the system one should not 
get bogged down by trying to understand the minute details of the system; rather one 
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should familiarise oneself with those aspects of the system that would yield insight when 
translated into mathematical formalism. The above thought is astutely summarised by 
Albert Einstein [wikiquote.org],  
 
“Things should be made as simple as possible, but not any simpler” 
 
The discussion of the biological aspects of HIV and TB was done with this thought in 
mind. From a mathematical modeller’s point of view one needs only to understand the 
underlying mechanism by which the observed biological interactions between HIV, TB 
and the immune system take place. Once these interactions are translated into 
mathematical formalism they present themselves as nonlinear differential equations. As 
one finds later in the dissertation, even simple-looking nonlinear differential equations 
which have simple underlying mechanisms of interaction, can produce exceedingly 
complex dynamics. Happily for us the converse holds true as well in that the complex 
immunological dynamics which take place within the human body can be reproduced by 
simple underlying mechanisms. Therefore, as a mathematical modeller one need not 
attempt to explain the minute details of the biology, rather one need only understand the 
underlying mechanisms of interaction which are necessary to build a successful model, a 
model that yields insight into the immunological dynamics. The nitty-gritty of the biology 
should be left to the biologist.  
 
However, with that said any person reading the biological account that follows in 
Chapters 2 to 4 will have a coherent and relevant understanding of the biology of HIV, 
TB and the immune system. Chapter 2 is dedicated to familiarising the reader with HIV, 
its transmission routes, molecular structure, characteristics of disease progression, 
replication cycle, drug therapies and historical accounts of the disease. Chapter 3 deals 
with describing the human immune system. The functioning and description of the 
immune system cells that are specifically involved during the pathogenesis of HIV and 
TB are described. Chapter 4 gives an account of Tuberculosis. A discussion is made of 
the epidemiological statistics, implications for coinfection with HIV, pathogenic 
mechanisms and the treatment of the disease. 
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The second part of the thesis, Chapters 5 to 8, presents the mathematical modelling aspect 
of the research, where the goal is to create a mathematical model of HIV-TB coinfection 
with treatment. In order to achieve this objective the following strategy was pursued. 
Initially the reader is familiarised with the mathematical modelling of biological systems 
by being introduced to various population models. Population models are relevant to 
modelling HIV since HIV models are merely in-host population models. This is followed 
by the review of various HIV models. Some of these HIV models included treatment 
mechanisms. The modelling of HIV-TB coinfection is then reviewed by the presentation 
of a previously developed HIV-TB coinfection model. All models reviewed – HIV, HIV 
with treatment and HIV-TB coinfection – made it possible to build a suite of models that 
each contained certain desirable mathematical features. Combining these different 
features separately and together culminated in the development of a final all-inclusive 
model of HIV-TB coinfection and its treatment.  
 
The strategy outlined above to develop a mathematical model of HIV-TB coinfection is 
presented in Chapters 5 to 8. Chapter 5 introduces the reader to mathematical biological 
modelling by simulating and analysing well-known population and predator-prey models. 
Chapter 6 reviews various HIV models. Model simulations, mathematical analyses and 
numerical bifurcation analyses are carried out. Mechanisms for simulating HIV treatment 
are added to the models. Treatment strategies and implication are discussed. Chapter 7 
presents a model for HIV-TB coinfection. Simulations and discussions of the various 
permutations that the model displays are undertaken. The culmination of the dissertation 
is presented in Chapter 8. A new model is developed by using some of the mathematical 
structures found in the models that were previously presented. The model contains 
mechanisms that are able to simulate both the treatment of HIV and TB. Model 
simulations are carried out to evaluate the dynamics displayed by the model. Thereafter, 
the various treatment strategies used to treat HIV-TB coinfection are evaluated. The final 
chapter, Chapter 9, forms the conclusion of the dissertation. This chapter reviews the 
motivation for the dissertation, the research problems that were posed and the aims and 
objectives of the dissertation. A summary of the results from the model of HIV-TB 
coinfection with treatment is made. These results are then used to offer possible 





Human Immunodeficiency Virus 
 
 
2.1. Basic Virology  
 
Viruses are pathogens that may cause death and disease to the living organisms that they 
infect. They are small particles that range in size from about 20 to 300 nano-           
metres [13, 29], and are probably the least complex of all life forms. In its basic form a 
virus consists of genetic material in the form of DNA or RNA. This is surrounded by a 
capsid, which is a casing composed of protein. Further to this it can also be encapsulated 
by a membrane consisting of a mixture of proteins and fatlike substances that serve to 
protect the viral genetic material [22]. Viruses are in fact so simple that they do not 
possess many of the characteristics used to define life. For example they cannot 
metabolise or reproduce on their own. In order to reproduce a virus must infect a living 
cell and use its host’s biological processes to replicate. Morbidity and mortality, which 
are associated with viral infection, are only side-effects of the virus’ primary reproductive 
objective.  
 
The virus’ life cycle is typically categorised into a few key events. The replication cycle 
begins with the virus attaching itself to the host cell, thereafter inserting its genetic 
material into its host. The viral genetic material is then exposed by an uncoating process 
and viral proteins are produced. These newly produced viral proteins manipulate the host 
cell to replicate the viral genome. Yet more viral proteins are produced for the coat and 
membrane of the nascent virus. Finally the virus particles are assembled and the new 
virions are released from the host cell. The virions may undergo internal structural 
changes once they have budded from their host cell to form a mature virus capable of 
causing infection. 
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2.2. HIV: An Overview  
 
Infection with Human Immunodeficiency Virus (HIV) results in Acquired 
Immunodeficiency Syndrome (AIDS), which is characterised by a failing immune system 
and susceptibility to opportunistic infections caused by fungi, bacteria, parasites and other 
viruses. Due to the collapsing state of the immune system the infected individual has an 
inability to fight off the constant assault of opportunistic infections, which finally results 
in death. 
 
Human Immunodeficiency Virus belongs to a category of viruses known as     
retroviruses [49, 99]. Retroviruses have their genome in the form of RNA which has to be 
translated into DNA during its lifecycle. This is generally the reverse of what usually 
occurs during the biological processes found in nature, hence the prefix ‘retro’. Typically 
most biological processes proceed from DNA to RNA. In addition to being a retrovirus 
HIV is also a lentivirus [20, 99]. Lentiviruses are characterised by long incubation 
periods and long duration of illness. This has grave implications for the epidemiology of 
the disease since HIV-positive individuals can remain asymptomatic for many years and 
not know that they are infected, while spreading the disease to many others. HIV 
infection is spread by the transfer of infected bodily fluids such as blood, semen, vaginal 
fluid, or breast milk [6], which contain HIV present as free virus or as infected immune 
cells. Transmission can occur during any process that transfers infected bodily fluids 
from one individual to another. Typical routes of transmission are unprotected sexual 
intercourse, sharing of unsterilised hypodermic needles, usually amongst intravenous 
drug users, blood transfusions and from mother to child during breast feeding and child 
birth [124, 137]. 
 
 
2.3. HIV Virion Structure 
 
The HIV genome encodes at least nine genes, these are - Gag, Pol, Env, Tat, Rev, Nef, 
Vif, Vpu and Vpr [99]. The first three genes are structural genes that encode for structural 
proteins used as building blocks, or are used in the construction of the building blocks, to 
Human Immunodeficiency Virus 
 7 
form the physical structure of new viral particles. The six remaining genes are regulatory 
genes, which encode for proteins that regulate the processes that the HIV virion performs, 




Figure 1: Structure of HIV virion [USA. Fed. Gov.]. 
 
 
A pictorial representation of an HIV virion is shown in figure 1. It is approximately 
spherical and has a diameter of about 120 nanometers [82]. The HIV virion’s outer    
layer (viral envelope) is composed mainly of a bilayer of phospholipids [114]. Newly 
formed HIV virions are coated with the phospholipids bilayer as the viral capsid (core) 
emerges from the host cell during the budding process. The surface of the viral envelop is 
studded with the gp160 glycoprotein complex [18, 153, 154], which consists of a cap 
made from the glycoprotein gp120 and a stem made from the glycoprotein gp41. The 
surface glycoprotein complex enables the HIV virion to bind and subsequently fuse its 
capsid, including its genetic material, into its host cell [18, 51]. Just below the viral 
envelope is a matrix composed of the protein p17 [53, 67, 89]. The p17 protein performs 
important functions throughout the viral life-cycle, including anchoring the glycoprotein 
gp41 onto the surface of the virus, assisting in viral penetration, transporting the proviral 
integration complex across the nuclear envelope, and localizing the assembling virion to 
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the cell membrane [89]. Contained within the p17 matrix is the viral capsid, which is 
conical in shape and is composed of the protein p24 [1, 19]. The capsid contains the 
genetic material of HIV in the form of two copies of single-stranded RNA and enzymes 
such as reverse transcriptase and integrase, which are essential to the viral production 
process [3, 132].  
 
 
2.4. HIV Replication Cycle 
 
The replication cycle of HIV can typically be broken down into a number of steps. These 
steps are listed as: 1. Virion Binding and Capsid Insertion; 2. Reverse Transcription and 
Integration; 3. Transcription and Translation; 4. Assembly, Budding and Maturation. 
 
 
2.4.1. Virion Binding and Capsid Insertion  
 
Since HIV virions cannot replicate on their own they need to manipulate the biological 
processes of their host cells in order to do so. When an HIV virion comes into contact 
with a cell expressing CD4 on its cell surface, the gp120 glycoprotein spikes that protrude 
from the surface membrane of the HIV virion bind to the CD4 receptors [26, 32]. This 
binding induces a conformational change in the gp120/gp41 glycoprotein complex which 
allows the gp120 glycoprotein to bind to the chemokine coreceptors CXCR4 or        
CCR5 [36, 38, 51, 146]. This in turn induces an additional conformational change that 
exposes the gp41 glycoprotein and facilitates the entry of the viral capsid into the host               
cell [18, 48, 78, 106]. 
 
 
2.4.2. Reverse Transcription and Integration  
 
Once the HIV virion has penetrated the cytoplasm of its host cell an uncoating step leads 
to the release of the viral RNA from its core [15]. The reverse transcriptase enzyme then 
copies the viral RNA into DNA [124]. The viral DNA is then transported into the nucleus 
of the host where the integrase enzyme facilitates the splicing of the viral DNA into the 
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host cell’s DNA [21, 152]. The viral DNA that has been integrated into its host genome is 
known as a provirus.  
 
 
2.4.3. Transcription and Translation  
 
In the nucleus of the cell transcription of the cellular DNA into RNA, which are used as 
blueprints for protein building, takes place. At the same time RNA copies of the viral 
DNA, which has been spliced into the cellular DNA, are produced [58]. These copies are 
messenger RNA (mRNA) and travel to the cell’s cytoplasm [47], where the Env 
precursor polyprotein gp160 is synthesized in the endoplasmic reticulum with subsequent 
post-translational modification of the Env polyproteins occurring at the endoplasmic 
reticulum and Golgi apparatus to form the gp120/gp41 glycoprotein complex [132]. The 
Gag and Gag-Pol polyproteins are synthesized in the ribosomes. The Gag polyprotein is 
the precursor to the matrix, capsid and nucleocapsid proteins [47, 65]. The Gag-Pol 
polyprotein is the precursor to the matrix and capsid proteins, as well as the protease, 
reverse transcriptase and integrase enzymes [119]. The polyproteins are transported to the 
cell membrane where viral assembly takes place.  
 
 
2.4.4. Assembly, Budding and Maturation  
 
During or after transport of the Gag and Gag-Pol polyproteins to the cell membrane the 
Gag precursor recruits two copies of the single-stranded viral RNA genome, interacts 
with the Gag-Pol precursor and assembles into structures lining the inner face of the 
plasma membrane [47]. The Env glycoproteins, which form the viral envelope spikes, are 
also incorporated into the assembled structures. The assembled Gag protein complex, 
which encapsidates the two copies of the viral genome, buds from the plasma membrane, 
see figure 2, taking some of the membrane with it [132]. At this stage the particles are not 
yet infectious. They go through a maturation process during which the Gag and Gag-Pol 
… 
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polyproteins are cleaved by the protease enzyme into the proteins and enzymes that make 
up a functional HIV virion and triggers the rearrangement of the cleavage products to 




Figure 2: Electron microscope image of HIV virion budding [CDC]. 
 
 
2.5. HIV Disease Progression  
 
The clinical course of HIV infection shown in Figure 3, leading ultimately to AIDS, 
varies between individuals in terms of viral load, symptoms and duration. However, there 
are four typical stages during disease progression that an HIV-positive individual 
experiences. These four stages were classified in 1990 by the World Health   
Organisation (WHO) [142] and are intended to be a means of establishing disease 
prognosis in a resource limited setting, such as one would typically find in Sub-Saharan 
Africa. These stages are classified as: Stage One – Primary Infection, Stage Two – 
Asymptomatic Infection, Stage Three – Symptomatic Infection, and Stage Four – AIDS. 
The World Health Organisation revised its classification of the various HIV stages         
in 2005; however, both classification systems are similar. For the sake of simplicity, as is 
necessary for mathematical modelling purposes, a review is made of the initial 
classification system.  
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Figure 3: Graph of generalised HIV disease progression [Wikimedia Commons]. 
 
 
2.5.1. Primary Infection  
 
Subsequently to initial infection with HIV viral replication commences in cells 
expressing CD4 receptors, primarily in CD4
+
 T cells. Individuals develop high viral loads 






 of blood [124], 
resulting in high numbers of infectious virus and infected cells circulating in the 
peripheral blood. Within five to six weeks individuals may develop acute HIV syndrome, 
which is characterised by flu-like symptoms. This lasts for about a week, at which time 
the immune system mounts HIV specific immune responses, and the individual’s flu-like 
symptoms disappear. This is accompanied by a decrease in the viral load of about one to 
two orders of magnitude, which is largely due to HIV specific CD8
+
 T cell immune 
response; however, a limitation in the number of cells susceptible to HIV infection could 
also play a part [124, 127]. The CD8
+
 T cells ability to decrease viral load is an important 
factor since the rapidity of disease progression is correlated with the level (set point) the 
viral load settles down to shortly after primary infection [91]. The set point viral load is 
characterised by being relatively stable over prolonged periods of time due to 
approximately equal rates of production and clearance of HIV virions.   
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2.5.2. Asymptomatic Infection  
 
The viral load settling to its set point value signals the onset of the asymptomatic phase. 
This phase is characterised by clinical latency, shown in Figure 3, during which the HIV-
positive individual remain free from any major symptoms. The typical duration of the 
asymptomatic phase is from 8 to 11 years [93, 129]. However, about 22% of individuals 
progress to AIDS within 5 years [96] and an estimated 8–15% of individuals will remain 
free from any AIDS defining illnesses for 20 years [95]. Even though HIV-positive 
individuals do not show AIDS related symptoms during this phase, the internal dynamics 
of the disease are not static in that there is a high turnover rate of HIV virions of the order 
10
10
 virions per day [107], accompanied by a gradual decline in the CD4
+
 T cell        
count [132].  
 
 
2.5.3. Symptomatic Infection  
 
Characteristic of disease progression through the various stages of HIV is an increase in 
viral load accompanied by a decrease in CD4
+
 T cell count [73]. The increase in viral 
burden is temporally associated with the emergence of viral mutants displaying enhanced 
pathogenicity [25]. The failing immune system coupled with the high viral loads allows 
opportunistic infection, which would otherwise be controlled by the immune system, to 
appear. The diseases and symptoms which characterise WHO stage 3 are: unexplained 
weight loss of more than 10%, chronic diarrhoea for more than a month, prolonged   
fever (constant or intermittent) for more than a month, oral thrush, oral hairy leukoplakia, 
pulmonary tuberculosis and severe bacterial infections (i.e. pneumonia, pyomyositis). An 
individual in stage 3 of HIV infection would typically be bedridden for up to 50% of the 
day towards the end of this stage.  
 
 
2.5.4. AIDS  
 
The final stage of disease progression is characterised by the severe impairment of the 
immune system with an associated CD4
+
 T cell count of less than 200 per mm
3
 of blood.             
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As a result a whole host of life-threatening opportunistic infections, c.f. WHO          
report [142], known as AIDS Related Complexes (ARCs) appear. Without antiretroviral 
therapy an individual with AIDS would live on average for 9.2 months [93]. The average 
survival time, using the present treatment strategies, of individuals diagnosed with AIDS, 
is in excess of 5 years [123].  
 
 
2.6. HIV/AIDS Drugs and Treatment Strategies  
 
Antiretrovirals, which have been approved to treat HIV, come primarily in two      
variants [124] – reverse transcriptase inhibitors and protease inhibitors. Protease 
inhibitors are designed to inhibit the activity of the HIV protease enzyme by preventing it 
from cleaving the Gag polyprotein into the proteins and enzymes that make up a 
functional HIV virion. Reverse transcriptase inhibitors are designed to inhibit the HIV 
reverse transcriptase enzyme from transcribing the viral RNA into DNA, thereby foiling 
an essential part of the HIV life-cycle. Reverse transcriptase inhibitors fall into two 
categories, nucleoside analogues or nonnucleoside analogues. Nucleoside analogues 
function as chain terminators. They are incorporated into the growing DNA molecule by 
mimicking the structure of the host cell’s DNA building blocks and thereby preventing its 
extension. Since they are structurally different from the host cells DNA when the viral 
DNA combine with these DNA building blocks they cannot integrate into the host cells 
DNA. A nonnucleoside analogue on the other hand binds to the HIV reverse transcriptase 
enzyme and disrupts the enzyme’s ability to transcribe the viral RNA into DNA.  
 
In addition to the above-mentioned antiretroviral drugs, there are several drugs in the 
developmental stage that target other key aspects of the HIV life-cycle. Fusion inhibitors 
block an HIV virion’s ability to fuse with a candidate host cell’s membrane, thereby 
rendering it unable to enter and infect the host cell. Integrase inhibitors disrupt the 
activity of the HIV integrase enzyme which facilitates the integration of the viral DNA  
… 
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into the host cell’s DNA. Entry inhibitors block an HIV virion’s ability to enter a 
candidate host cell by binding to the CCR5 chemokine coreceptor, a vital mechanism of 
host cell entry. 
 
Current treatment strategy for HIV is termed HAART (Highly Active Antiretroviral 
Therapy). There is much debate about the optimal timing during disease progression 
when HAART should commence. However, HAART is typically commenced when an 
individual’s CD4
+
 T cell count is less than 200 per mm
3
 of blood or when an           
AIDS-related complex has been identified. HAART has several adverse side-effects; 
however, this is outweighed by its ability to reduce morbidity and mortality. Nevertheless 
HAART cannot completely eradicate HIV so treatment is generally continued for the 
duration of the illness [124]. HAART consists of a combination of at least three drugs 
belonging to two different classes, typically two nucleoside analogue reverse 
transcriptase inhibitors and either a protease inhibitor or a nonnucleoside analogue 
reverse transcriptase inhibitor. By combining these antiretroviral drugs one is able to 
suppress viral replication to low levels, thereby decreasing viral load and giving the 
immune system an opportunity to recover. Equally importantly, by slowing down the 
HIV replication rate, the emergence of drug-resistant HIV mutants is at least delayed if 
not prevented [124].  
 
 
2.7. Viral Mutations and Drug resistance  
 
Viral mutations are a consequence of the high HIV virion turnover rate of the order 10
10
 
virions per day [107] and the fact that the reverse transcription step, which transcribes the 
genomic viral RNA into proviral DNA, is highly error prone and lacks proof-reading 
capabilities [112, 117]. This results in the production of genetically heterogeneous HIV 
virions, characterised by the appearance of mutant strains of the disease. Genetically 
heterogeneous HIV virions, called quasispecies, can have up to 15% diversity between 
them in an HIV-infected individual [88]. Genetic variation is thought to be one of the 
primary factors which enable HIV to escape eradication by the immune system.  
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During antiretroviral therapy the selective forces to which the viral mutants are subjected 
allow the virus to develop drug resistance; moreover HIV drug-resistant strains can be 
transmitted from one individual to another [148]. HIV mutants, with varying degrees of 
resistance, have been found for all drugs that have been used, or are being considered for 
use, as anti-HIV therapy [23]. The emergence of anti-HIV drug resistance is the most 
common cause of treatment failure. Nevertheless treatment failure due to drug resistance 
can be reduced by ensuring strict compliance with the antiretroviral administration 
routine and by using a cocktail of multiple antiretroviral drugs simultaneously, in most 
cases three drugs, which slows the replication rate of the virus, thereby curtailing the 
mutation rate.  
 
 
2.8. Origin of HIV  
 
HIV seems to be a zoonotic infection crossing species from African chimpanzees to 
human beings [52, 63] establishing two different strains of the disease. HIV-1 and HIV-2 
are genetically distinct and crossed from different chimpanzee subspecies [80]. HIV-1 is 
responsible for the global HIV pandemic; therefore all references to HIV in this 
dissertation pertain to HIV-1 unless otherwise explicitly stated. HIV-1 is closely related 
to a strain of Simian Immunodeficiency Virus, classified as SIVcpz, harboured by the Pan 
Troglodytes Troglodytes chimpanzees native to West Equatorial Africa [52]. The 
geographic location of origin of HIV-1 is most likely the Democratic Republic of Congo. 
Infected individuals in that country have a constant and extremely high genetic diversity 
of HIV-1 stemming from the likelihood that the disease was present there for the longest 
period, having more time to mutate relative to anywhere else on the globe [134, 135]. 
Estimates of the timescale of SIVcpz crossing species into human beings, introducing the 
HIV-1 disease, place the event around 1930 [80, 121].  
 
The HIV-2 strain is less virulent and not as easily transmissible as HIV-1 and is largely 
confined to West Africa [83]. Like HIV-1, however, HIV-2 is also closely related to a 
strain of Simian Immunodeficiency Virus, classified as SIVsm, harboured by the Sooty 
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Mangabey monkeys indigenous to West Africa [52]. A reconstruction of the HIV-2 
lineage puts the likely location of SIVsm crossing species to establish the HIV-2 disease in 
the West African country of Guinea-Bissau around 1940; however, the disease only 
experienced rapid exponential growth, establishing itself as an epidemic, during the 
period 1955–1970 [111]. This period coincides with Guinea-Bissau’s war for 
independence which most likely created the social conditions necessary for the rapid 
spread of the disease [83].  
 
 
2.9. History of HIV  
 
The earliest cases of HIV on record are plasma samples taken in 1959 of a man in the 
Democratic Republic of Congo [155], tissue samples of an American teenager who died 
in Saint Louis in 1969 [103] and tissue samples of a Norwegian sailor who died around 
1976 [72]. It was, however, only in 1981 that the disease was clinically diagnosed and its 
existence brought to the attention of the global medical community when a group of 
homosexual men in Los Angeles, San Francisco and New York were afflicted by rare 
diseases caused by the suppression of the immune system [101].  
 
In 1969, when the disease was initially introduced into the United States of America, it 
was unable to take off. Possible reasons for this could be that the disease needed carriers 
who engaged in frequent sexual intercourse with large numbers of partners in order to 
establish itself as an epidemic, a condition that was likely met by the homosexual 
population that initially carried the disease. By 1982 there were over 800 cases of AIDS 
in the United States. It spread from the initial homosexual population to haemophiliacs, 
who received blood derived products from donors, intravenous drug users, and the 
heterosexual population. 
 
With the disease rapidly spreading, the search was now on to identify its causative agent. 
In 1983 Luc Montagnier and his team, working at the Pasteur Institute in Paris, identified 
the presence of a retrovirus in the lymph node tissue obtained from infected      
Human Immunodeficiency Virus 
 17 
individuals [4]. Soon afterwards Robert Gallo and his team, working at the National 
Institute of Health in Bethesda, Maryland, were also able to identify the retrovirus from 
infected patients [50, 122]. In addition the team at the NIH was able to multiply the 
retrovirus in continuous culture and was thereby able to develop a specific test for the 
disease [110]. This was a significant step which now gave health workers the ability to 
accurately diagnose the status of infected individuals and identify contaminated blood 
samples.  
 
Since then there has been a wealth of research performed on the disease and numerous 
important features of the retrovirus’ structure and dynamics have been established. 
Nevertheless there is still no vaccine or cure for the disease and there remains much 
research to be done in order to improve our understanding of the disease so that a vaccine 






Human Immune System 
 
 
3.1. Immune System: An Overview  
 
The immune system consists of organs, tissues and cells that function as an integrated 
unit to protect the body by overcoming infection due to pathogens such as viruses, 
bacteria, fungi and parasites. The immune system consists of the lymph vessels, lymph 
nodes, thymus, spleen, bone marrow and an elaborate network of interacting white blood 
cells [29]. At a fundamental level the immune system defence can either be           
adaptive or innate.  
 
The adaptive immune system response is specific in that it adapts the immune response to 
maximise its effectiveness to eliminate a specific pathogen. After the immune system has 
eliminated the pathogen, it develops immunological memory whereby it is able to launch 
a quicker and more effective defence against the pathogen if it subsequently reappears.  
 
The innate immune system response is nonspecific. It does not differentiate between the 
different types of pathogens that initiate the immune response. Thus it deals with all 
pathogens in a generic way. As a consequence of its generic manner, even for pathogens 
it has encountered before, the innate immune system does not develop immunological 
memory. Previous exposure to the pathogen would not be of any added advantage during 
future encounters.  
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3.2. Immune System Cells  
 
White blood cells are the major protagonist of the immune system’s defence against 
foreign substances (antigens). There are various subcategories amongst white blood cells 
that perform important functions in a healthy immune system. Foremost among these are 
the lymphocytes, which are made up of B cells and T cells, as well as the phagocytes, 
namely the macrophages.  
 
 
3.2.1. B cells  
 
B cells are produced in the bone marrow. They are able to recognise antigens that invade 
the body. B cells have antibody molecules on their cell surface that are able to identify 
localised regions, known as antigenic determinants, found on the surfaces of antigen 
molecules. The antigen binding site, found on specific regions on the antibody molecule, 
binds to an antigen if the antigenic determinant and the antigen binding site have 
complementary shapes and fit like a lock and key. The ability to combine the protein 
subunits that make up the antibody molecule in a vast number of different ways ensures 
that the antibody molecule binds to almost any antigen entering the body. 
 
When the diverse array of B cells, each with differing antibody molecules on their cell 
surface, encounter an antigen only the B cell with the antibody molecule that best fits the 
antigenic determinant of the given antigen is activated to divide and form clones. This 
process, called clonal selection, ensures a high specificity for antibody-antigenic binding. 
Adding further to the specificity of the process is somatic mutation, whereby antibodies 
with slightly differing shapes are produced and might have a greater binding affinity to 
the given antigen. Variants that bind better have a stronger signal to multiply, thus 
replicating more rapidly and effectively outcompeting the other B cells that do not have 
as high a specificity. This process, called affinity maturation, ensures optimal specificity 
of the antibody-antigen binding. The stronger replication signal that accompanies the 
dynamics of greater specificity also ensures that large numbers of antibodies are            
… 
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produced only when the body needs them. Furthermore in subsequent encounters with the 
given antigen the immune system is able to launch a faster and more effective attack due 
to some clones becoming long-lived memory cells. 
 
B cells release their antibody molecules into the blood. The antibodies mark the pathogen 
for elimination by other immune cells such as, for example, phagocytes and the 
complement system of blood enzymes. The antibodies might even be able to neutralise 
the pathogen on their own by forming a coating so dense that it effectively prevents the 
pathogen from reproducing or invading target cells.  
 
 
3.2.2. T cells  
 
T cells are produced in the bone marrow, but undergo a maturation process in the thymus 
where they develop into functional immune cells that are differentiated according to the 
various tasks that each subcategory of T cells is required to carry out. The CD8
+
 T cells 
are the killer cells, while the CD4
+
 T cells are the helper cells. They are differentiated by 
the CD (cluster of differentiation) glycoprotein T cell receptor on their cell surface, either 
CD4 or CD8.  
 
Vital to the proper functioning of the immune system is its ability to differentiate between 
self and nonself, ensuring it does not mount an immune response against its own cells and 
tissues by falsely identifying them as foreign, as is the case during autoimmune disease. 
The task of differentiating between self and nonself lies with the T cells.  
 
When a virus infects a T cell, it undergoes antigen processing whereby the cell processes 
the viral proteins into smaller fragments, known as peptides. Parts of the peptides are then 
bound on the cell surface to the Major Histocompatibility Complex (MHC) molecules.    
T cell receptors bind to these MHC-peptide complexes; however, the interaction has a 
high degree of specificity and binding only occurs according to fit, analogously to the 
lock and key mechanism. During the T cell maturation process in the thymus, cellular 
peptides of immune system cells form MHC-peptide complexes that are presented to the 
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T cells for binding. Those T cells that are adequately able to bind to the MHC-peptide 
complexes are allowed to survive. The remaining T cells die by apoptosis, a process of 
programmed self destruction of cells. This mechanism of identifying T cells that are able 
to bind to MHC-peptide complexes is known as positive selection. However, in order to 
ensure that the T cell do not mistake normal cellular peptides for pathogenic peptides, the 
T cells also undergo negative selection. During negative selection those T cells that bind 
only weakly with self MHC-peptide complexes are allowed to survive. The rest of the T 
cells, which bind too strongly with the self MHC-peptide complexes, also undergo 
apoptosis in order to avoid autoimmune disease. T cells that survive the positive and 




 T cells, which are 
differentiated by the class of MHC molecule on antigen presenting cells to which their 
receptors bind. CD8
+
 T cell receptors bind to MHC class one (MHC-1), while CD4
+
 T 









 T cells are cytotoxic. If a cell is infected by a virus, the cell processes the viral 
proteins into antigenic peptide fragments and transports them to the cell surface where 
they are bound to MHC-1. The MHC-peptide complexes are presented on the cell 
surface. CD8
+
 T cells with the correct specificity are able to bind to the MHC-peptide 
complex and kill the infected cells by the release of perforins, proteins that cause death to 
the cell by puncturing its cellular membrane [14]. Once the CD8
+
 T cells are activated 
they undergo clonal expansion, producing more CD8
+
 T cells of the same specificity 
ready to kill the remaining virally infected cells. CD8
+
 T are also equipped with 
chemicals and defence mechanisms that can inhibit infected cells from replicating or 









 T cells cannot by themselves kill infected cells. Nevertheless they do have an 
important role to fulfil in terms of regulating and optimising the various aspects of      
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cell-mediated immunity, for example CD4
+
 T cells are necessary for the proliferation of 
activated CD8
+
 T cells. They also fulfil a crucial role when establishing an antigen 
specific antibody immune response. Antigen Presenting Cells (APC), such as 
macrophages and B cells, internalise pathogens and present antigenic peptides bound to 
MHC-2 on their cell surface, which are then recognised by CD4
+
 T cells. CD4
+
 T cells of 
the correct specificity that are able to bind to the MHC-peptide complex ensure that the B 
cells are able to distinguish between self and nonself, while signalling to the B cells to 




3.2.3. Macrophages   
 
Macrophages are phagocytes that engulf and digest antibody-bound pathogens and other 
debris, such as dust, dead cells and tissue. Macrophages are derived from monocytes, 
white blood cells produced in the bone marrow that mature through a series of changes to 
become a macrophage. As is the case with B cells, macrophages are also antigen 
presenting cells. Subsequently to digesting an antigen they break the antigen down into 
smaller peptide fragments and present the antigenic peptides bound to MHC-2 on their 
cell surface. Circulating T cells are then able to recognise this MHC-peptide complex and 
become activated to mount a specific immune response against the antigen, which 
includes the stimulation of B cells to produce more antibodies for the given pathogen. 
Antibody-coated pathogens are cleared more easily by the immune system. This    
antigen-specific immune response strengthens the ability of the immune system to 







"We cannot win the battle against AIDS if we do not also fight TB. TB is too often a death 
sentence for people with AIDS. It does not have to be this way." 
– Nelson Mandela, XV International AIDS conference, Thailand 2004 
 
 
4.1. Tuberculosis: An Overview  
 
Tuberculosis (TB) is a contagious disease which typically results from being infected 




Figure 4: Electron microscope image 
of Mycobacterium tuberculosis [CDC]. 
 
 
TB is one of the oldest known diseases, with evidence of infection found in the vertebra 
of Stone Age Man and Egyptian mummies; as well as in records from ancient Greece, 
Rome, India, China and medieval Europe [55, 94, 98]. TB infection is spread through the 
air. It occurs by the inhalation of aerosol bacilli of its causative agent. TB commonly 
infects an individual’s lungs. This form of TB is known as Pulmonary Tuberculosis. As a                           
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result of active infection granulomas subsequently develop at infected sites in the lungs. 
These granulomas consist predominantly of aggregates of T cells and TB infected 
macrophages [68]. Granulomas undergo cell death, referred to as necrosis. Lung 
cavitation can result from necrosis due to the destruction of lung tissue. TB infection is 
not only confined to the lungs. Infection in other organs and tissues does occur as a result 
of bacilli migration via infected dendritic cells and peripheral blood.  
 
 
4.2. Tuberculosis Epidemiology  
 
TB is a major public health problem in most of the developing world. In Sub-Saharan 
Africa the problem is aggravated by the fact that TB is the main opportunistic disease of 
HIV [34, 40, 61]. As data became available, the World Health Organisation was able to 
make estimates for HIV-TB epidemiology for 2000, then 2002 and recently for 2004. 
Estimates for 2000 showed that TB infections attributable to HIV in WHO African 
member states was about 31%, with South Africa estimated to have had 2 million of the 
global total of 11 million HIV-TB coinfected individuals [27]. The 2002 estimates for 
HIV prevalence amongst adult TB patients revealed that Southern Africa faced grim 
prospects, with Zimbabwe (75%) and South Africa (60%) ranking amongst the worst 
affected [144]. Estimates for 2004 showed coinfection prevalence for the African 
continent increased to about 33%, with Southern African countries still faring poorly – 
Swaziland (81%), Botswana (77%), Lesotho (76), Zimbabwe (68%), Namibia (61%), 
South Africa (60%), Zambia (54%) and Malawi (52%) all being severely affected [145].  
 
 
4.3. Tuberculosis-HIV Coinfection  
 
Many people infected with HIV develop TB as the first manifestation of AIDS.         
HIV-positive individuals do not have the internal immune system resources to keep TB in 
check. In fact they are more than 20 times likely to develop active TB than people who 
are HIV-negative as the suppression of the immune system worsens [115]. Studies have 
shown that the host’s immune response to the TB bacterium enhances HIV replication 
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and might accelerate the natural progression of the HIV infection [57, 97, 149]. In 
addition HIV can also accelerate disease progression in TB infection [31]. Therefore 
without treatment dually-infected individuals succumb to coinfection at a rapid rate. 
 
 
4.4. Tuberculosis Pathogenesis  
 
The etiological agent of TB is Mycobacterium Tuberculosis, first identified in 1882 by 
Robert Koch [79]. Mycobacterium Tuberculosis is an intracellular pathogen primarily 
infecting macrophages. TB infection begins when an uninfected individual inhales 
aerosol droplets containing Mycobacterium Tuberculosis. TB bacilli are expelled from 
the lungs of infected individuals when they cough. Once the bacilli are airborne they are 
inhaled by other individuals and typically get lodged in their alveoli, the tiny air sacs of 
the lung where gaseous exchange of oxygen and carbon dioxide take place [56]. Here the 
pathogen is engulfed and ingested by alveolar macrophages. Normally once pathogens 
have been phagocytosised by macrophages, they are transported to the macrophage’s 
lysosomes, where digestive enzymes break down and destroy the pathogen. However, it 
seems that mycobacteria may be able to block their delivery to the lysosomes enabling 
them to survive within the macrophages and start to replicate [68]. The ability of bacilli 
to evade the initial nonspecific immune response depends upon various factors. These 
include the state of the immune system, where diseases like HIV may inhibit immune 
responses, as well as the virulence factor of the mycobacteria [125]. The more virulent 
strains of TB are characterised by greater transmissibility and produce greater morbidity 
and mortality in infected individuals. 
 
The replication of bacilli within the macrophages attracts blood monocytes that mature 
into macrophages and ingest the released bacteria. During this stage in disease 
progression symbiosis occurs between bacteria and macrophages, with neither population 
eliminating the other. Bacteria continue replicating while blood-derived macrophages 
continue arriving. Macrophages that have ingested the mycobacteria process and present 
mycobacterial antigens to T lymphocytes. Two to three weeks after infection cell-
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mediated immunity develops with the arrival of antigen-specific T lymphocytes that 
intensifies the immune response and activates macrophages to kill the intracellular 
mycobacteria [133]. In addition to the activated cell-mediated response the immune 
system also initiates an inflammatory response. The inflammatory response serves to 
inhibit dissemination of the mycobacteria by encapsulating mycobacteria infected 
macrophages, activated macrophages, and T cells within granulomas. The granulomas 
subsequently develop central areas of necrosis which kill most of the mycobacteria; 
however, the pathogen is almost never totally eradicated. Nevertheless, the vast majority 
of the TB-harbouring population, approximately 90% of TB infected individuals, are able 
adequately to contain the bacteria and do not progress to any symptoms of active          
TB [46]. In fact it is estimated that latent TB may be carried by a third of the global 
population [42]. From the remaining 10% of infected individuals the immune systems of 
approximately 5% are not able to adequately contain the bacteria and active TB results 
within a year of infection, with the other 5% going on to develop active TB at some later 
stage in life [139]. Immunosuppression, such as infection with HIV, greatly increases the 
risk of reactivation of latent TB amongst previously infected individuals. Under these 
conditions granulomas can become liquefied and are able to serve as a rich medium for 
the revived bacteria to replicate prodigiously [125].  
 
 
4.5. Tuberculosis Treatment  
 
The treatment of TB aims to cure patients of the disease, prevent death from active TB, 
prevent relapse of TB, decrease disease transmission and prevent development of 
acquired drug resistance [143]. In order to achieve these aims a combination of anti-TB 
drugs are used. The most widely used first-line treatment anti-TB drugs are Isoniazid, 
Rifampin, Pyrazinamide and Ethambutol. A typical treatment regimen involves taking 
Isoniazid, Rifampin, Pyrazinamide and Ethambutol for two months, then Isoniazid and 




drug intake regime as skipping a treatment or not completing the full course could result 
in a multidrug resistant strain of TB. Multidrug resistant TB takes longer to treat, 
treatment is more expensive, side-effects associated with the treatment are greater and 
treatment success rates are smaller.  
 
In order to avoid such complications a TB control strategy has been developed from the 
collective best practices, clinical trials and programmatic operations of TB control over 
the past two decades [126]. This strategy, known as Directly Observed Treatment Short-
course (DOTS), is widely regarded as being the most effective strategy for treating TB 
and is recommended by the World Health Organisation. The South African Department 
of Health has also adopted the DOTS strategy to treat TB by implementing its core 
features [126], which involve sputum smear microscopy to detect infectious cases among 
people attending health care facilities with symptoms of TB, standardised short-course 
anti-TB treatment with direct observation of treatment, an uninterrupted supply of TB 
drugs and a standardised recording and reporting system which allows assessment of 
treatment results.  
 
 
4.5.1. Antituberculosis Drugs  
 
4.5.1.1. Rifampicin   
 
Rifampicin may be bacteriostatic, by inhibiting the multiplication of bacteria, or 
bactericidal, in that it kills bacteria. The bacteriostatic or bactericidal action of 
Rifampicin depends on the susceptibility of the bacterial species and the concentration of 
the drug. In the case of M. tuberculosis Rifampicin is bactericidal. In particular it 
possesses early bactericidal activity against active and semidormant bacterial populations, 
producing a sterilizing effect [71, 130]. Rifampicin inhibits the action of DNA-dependent 
RNA polymerase [17, 70], which is the enzyme that promotes the synthesis of RNA 
using a DNA or RNA template, thereby leading to the suppression of RNA synthesis and 





4.5.1.2. Ethambutol  
 
Ethambutol is used in the initial phase of TB treatment primarily to prevent drug 
resistance to Rifampicin [7]. Ethambutol is generally considered to have a bacteriostatic 
effect on M. tuberculosis when used at typical doses during TB treatment [5]. The exact 
mechanism of interaction between Ethambutol and M. tuberculosis is still unknown; 
however, several hypotheses have been advanced. The most prominent amongst these 
theories propose that ethambutol interferes with the biosynthesis of arabinogalactan, a 
constituent of the mycobacterial cell wall [37]. A further theory suggests that Ethambutol 
acts as a chelating agent, capable of forming bonds with metals, and disrupts and 
deactivates one of several metal-containing enzyme systems in the nucleic acid structures 
of mycobacteria [90].  
 
 
4.5.1.3. Isoniaziad  
 
Isoniazid is bacteriostatic against dormant and semidormant mycobacteria and 
bactericidal against rapidly dividing mycobacteria. Its primary use stems from its potent 
early bactericidal action against actively dividing mycobacteria. Isoniazid’s therapeutic 
mechanism results from its ability to inhibit the synthesis of mycolic acids, a major 
constituent of the mycobacterial cell wall [140]. Isoniazid inhibits the biosynthesis of 
mycolic acids by specifically targeting the enzyme InhA, which is essential to the 
biosynthesis process [118]. Mycolic acids form a lipid shell, which serves to determine 
permeability properties at the cell surface. They endow several unique characteristics to 
M. tubeculosis and are important to the growth, survival and pathogenicity of the 





The concomitant use of Pyrazinamide with the other anti-TB drugs plays a unique role in 
shortening TB therapy from the previous 9–12 months to 6 months [151]. Pyrazinamide 
exerts its therapeutic effects by inhibiting the synthesis of fatty acids in M. tuberculosis 
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by disrupting the activity of the enzyme fatty acid synthetase I [156]. The drug is 
converted into its active form, pyrazinoic acid, by the M. tuberculosis enzyme 
pyrazinamidase. Pyrazinamidase, and consequently pyrazinamide, are only active at an 
acidic pH [150]. Once in its active form the drug shows bactericidal activity against      
M. tuberculosis, including bacilli within macrophages, presumably because of its acidic 
intracellular ph [5]. Its importance within the anti-TB drug regime stems from its 
sterilizing ability of dormant and semidormant tubercle bacilli, which are unaffected by 









Mathematics can be applied to various systems in nature in order to gain qualitative and 
quantitative insight into the system. One can use mathematics to develop a model of the 
system, as has been the case in this dissertation where the aim was to develop a 
mathematical model of the interaction between HIV, TB and the human immune system, 
including the effects of drug therapy.  
 
Many systems found in nature can be modelled by nonlinear coupled differential 
equations. Mathematical modelling is an iterative process in which one refines the model 
by successive iterations. The steps involved in modelling natural phenomena, as can be 
seen in Figure 5, are studying the phenomena, formulating a mathematical model of the 
phenomena, solving the model analytically or computationally, analysing and interpreting 
the solution, using the results to make predictions and gain insights about the phenomena 
and testing the validity of the insights and predictions.  
 
Before a mathematical model is formulated one has to construct a verbal model of the 
underlying mechanisms of interaction of the system. One must then identify and 
understand the various parameters and variables that make up the system. Thereafter, one 
can combine the parameters and variables to form mathematical equations that follow 
certain rules, which according to our experience and knowledge, govern the system. 
Often in order to make the equations mathematically tractable one has to simplify and 
generalise these rules. Thus in essence most mathematical models are only idealised 
approximations of the phenomena being studied. The model does not necessarily have to 
reproduce exactly what happens in nature. It needs only to reproduce the salient features 
of the system so that one is able to approximate its future behaviour, as well as make 




After the initial steps of studying the system and building the mathematical model have 
been completed, the next step is to find solutions to the equations. In general one cannot 
solve the equations analytically; therefore one has to resort to computational techniques. 
After solving the equations an analysis of the solution/s can be undertaken. This analysis 
can be used to make predictions and gain insights into the system. The predictions and 
insights that the model yields can then be tested on the system itself. If the predictions 
and insights do not agree well with observations or experimental results from the system, 
the iterative loop of Figure 5 must be traversed once again in order to refine and enhance 




Figure 5: Flowchart of mathematical model development [128]. 
 
 
5.1. Population Models  
 
Population models are of interest when modelling the interaction of the immune system 
with pathogens such as HIV and TB. This is simply because one can think of the 
pathogen and the immune system cells as interacting populations and then model how 
coexistence affects each population. Such models can be useful in attempting to explain 
what factors in the form of model parameters, such as drug therapy and frequency and 
duration of therapy, eliminate or at least contain the pathogen population at low levels, 
while maintaining the cell population of the immune system at adequate levels. 
Alternatively, as would be relevant in HIV modelling, one can gauge what factors 
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facilitate the rapid onset of AIDS, characterised by an increase in the HIV virion 
population and decrease in the cell population of the immune system, so that one can take 
the necessary preventative measures in order to negate these factors. 
 
 
5.1.1. Fibonacci Sequence  
 
A forerunner of population models dates back to 1202 when the Italian mathematician 
Fibonacci published a problem about the breeding of rabbits. The question Fibonacci 
posed was the following, “How many pairs of rabbits can be produced from a single 
male/female pair assuming that the rabbits only reproduce after their first month and 
thereafter produce a male/female pair regularly at the end of every month without any 
rabbits dying?”  
 
The model that simulates rabbit breeding based on the Fibonacci assumptions is given by 
a recursive relationship [43] and generates the famed Fibonacci sequence.  
 
2 integers21 NRRR NNN , (1) 
 
 
where NR  denotes the number of rabbit pairs alive at the end of month N . The initial 
conditions are given by 10R , since there is only one pair of rabbits at the beginning, 
and 11R , since the initial pair only start reproducing after the first month. Applying the 
initial conditions and solving recursively for eqn. (1) one obtains the Fibonacci  
sequence: 1, 1, 2, 3, 5, 8, 13, 21, 34, 55, 89, 144, 233, …  
 
The Fibonacci sequence representation of the growth curve of the rabbit population is 
plotted in Figure 6 over the period of a year. One notes from the steep curve that the 




Fibonacci sequence demonstrates its value by being able to predict, even if one did not 
have any prior knowledge, the rapid growth of a rabbit population with no environmental 
restrictions. 
 

















Figure 6: Plot of Fibonacci sequence 
representing growth of rabbit population. 
 
 
5.1.2. Predator-Prey Model  
 
Modelling the interaction of HIV or TB with immune system cells takes the form of an    
in-host population model. More specifically the population model is a predator-prey type 
model. This type of model assumes the existence of interacting species in which a subset 
of the population, known as the predators, kills other members of the population, known 
as the prey. In the context of modelling the interaction of pathogens with immune system 
cells one finds that, since one subset of the population is killed by another subset of the 
population, one can simulate the interaction using predator-prey type models [33].  
 
 
5.1.2.1. Lotka-Volterra Equations  
 
One of the benchmark predator-prey models is called the Lotka-Volterra model. It was 
proposed by the Italian mathematician Vito Volterra in 1926 to explain variations in the 
shark and fish populations in the Adriatic Sea after World War One [138]. A similar 
model was previously independently developed by the American biophysicist Alfred J. 




Suppose there are two species that coexist in a given habitat. Assume that these species 
are rabbits )(R , which are the prey, and wolves )(W , which are the predators, and that 
the following assumptions hold. 
 
 
i. The birth rate of rabbits is proportional to the rabbit population with 
proportionality constant . 
ii. The primary cause of rabbit deaths is due to wolves and rabbits are killed by 
wolves at a rate  which is proportional to the rabbit and wolf populations. This 
follows from the fact that the more wolves and rabbits there are, the greater the 
likelihood that a rabbit will encounter a wolf and be killed by it. 
iii. The birth rate of wolves is proportional to the wolf population and the 
availability of food (rabbit population) with proportionality constant .      
iv. The death rate of wolves is proportional to the wolf population with 
proportionality constant . 
 
 
Combination of the above assumptions and then translation into mathematical formalism 












Parameters , ,  and  are all positive. The first and second terms in eqn. (2a) are 
due to assumptions i and ii respectively, whereas the first and second terms in eqn. (2b) 







One can analyse the Lotka-Volterra model qualitatively by linearising the system close to 
the equilibrium points. This is accomplished by computing the Jacobian matrix at the 






J . (3) 
 
 
By equating eqn. (2a) and eqn. (2b) to zero and solving for R  and W  one finds that the 
system has equilibrium points at  
 
,and0,0,WR . (4) 
 
 









J . (5b) 
 
 
In order to find the eigenvalues )(  of the linearised system at the equilibrium points one 
must solve the characteristic equation at those equilibrium points. 
 
0,0at    0
0
0





,at    0detdet 2IJ . (6b) 
 
 
Solving for  in eqns. (6a) and (6b) one obtains  
 
0,0at, 11  (7a) 
,at, 21 ii . (7b) 
 
 
From eqn. (7a) one notes that 0,0,WR  is saddle point, whereas from eqn. (7b) one 
sees that the point ,,WR  is a centre. Biologically speaking 0,0,WR  is a 
trivial equilibrium point because both the predator and prey populations are zero. On the 
other hand ,,WR  is more interesting. One can confirm that it is indeed a 
centre by analysing graphical solutions of the Lotka-Volterra equations. As an example 
substitute into eqn. (2) 
 
00002.0,02.0,001.0,08.0 . (8) 
 
 














The equilibrium solutions to eqn. (9) are given by substituting eqn. (8) into eqn. (4). 
 
 





One can analyse eqn. (9) by drawing its slope field, as has been done in Figure 7a, where 
the point 1000,80 ,WR  can clearly be seen to be an equilibrium point. Moreover by 
graphing a few typical solutions (phase trajectories) onto the slope field one obtains 
Figure 7b, which is the phase portrait of the Lotka-Volterra system. Figure 7b graphically 
confirms the theoretical observation that the equilibrium point 1000,80 ,WR  is a 
centre. Numerical solutions to the initial value problem 1000R  and 40W  for      
eqn. (9) are plotted in Figure 8a and Figure 8b for the rabbit and wolf populations. 
 
 
a. Slope field 












b. Slope field with phase trajectories 












Figure 7: Slope field and phase portrait of the Lotka-Volterra system. Notice that the system has 





a. Rabbit population  












b. Wolf population  
















As a consequence of the cyclic orbits of Figure 7b the rabbit and wolf populations track 
each other over time. By plotting in Figure 9 both the rabbit and wolf populations on the 
same set of axes this phenomenon is clearly discernable. 
 

























Figure 9: Superimposing the solutions to the Rabbit and Wolf 
populations. Note that they track each other over time. 
 
 
The Lotka-Volterra model is a relatively simple model; however, when tested against 
ecological data, it does seem to display the qualitative behaviour that has been observed 
in certain predator-prey systems. As an example, one can view in Figure 10 records of the 
Canadian Lynx and Snowshoe Hare populations between 1845 and 1935 obtained from 
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the records of the Hudson’s Bay Company in Canada which traded animal furs. One finds 
that the qualitative behaviour, in terms of the coupled oscillations of the predator-prey 
populations, predicted by the Lotka-Volterra model does actually occur in nature. 
 
 
Figure 10: Ecological data of lynx-hare predator-prey system. One finds that 
the coupled oscillations shown in solutions to the Lotka-Volterra system are 
indeed found in nature [147]. 
 
 
The numerical solutions of the Lokta-Volterra equations, and all other models presented 
in this dissertation, were obtained by implementing explicit Runge-Kutta methods. 
Consider the initial value problem for a system of ordinary differential equations given as 
))(,()( xyxfxy  for bxa  where we are given )(ay . The Runge-Kutta         
method [9] produces approximations nŷ  to )( nxy  for bxxxa n...10 . Each step 
from nx  to 1nx  involves two approximations to )( 1nxy , namely 1ˆ ny  and 1ny . The 















ˆ  (11b) 
where  
















jii ac ,   si ,...,,3,2 . (11e) 
 
To specify a particular Runge-Kutta method one needs to specify the integer s , i.e. the 
number of stages, and the coefficients jia ,  for sij1  and ib  for si ,...2,1 . In this 
dissertation the Runge-Kutta (4,5) pair of Dormand-Prince [39] and Runge-Kutta (2,3) 
pair of Bogacki and Shampine [8] were used. The Dormand-Prince pair works well as a 
general purpose ordinary differential equation (ODE) solver whereas the Bogacki-
Shampine pair is better suited for stiff ODEs. These routines were run in MATLAB  
where they are programmed as built in functions. Although all the models in this 
dissertation were solved by numerical techniques, we point out as a matter of interest 
that, analytical techniques to solve similar sets of equations do exist, for example c.f. the 






HIV-Immune System Models 
 
 
Having worked through the formulation and analysis of the Lotka-Volterra predator-prey 
system, one can now think of developing a similar predator-prey model for the interaction 
of HIV virions with the human immune system cells. As was previously noted, the 
immune system cells interacting with HIV virions can be modelled as a predator-prey 
system due to the fact that one subset of the population is killed off by another subset of 
the population. To begin with one can look at a simple model of HIV and immune system 
interaction commonly referred to in the literature as the basic HIV model. 
 
 
6.1. Basic HIV-Immune System Model  
 
The basic HIV model [64, 98, 115, 141] describes immune system cells interacting with 
HIV virions. The model contains three variables. These variables denote the populations 
of the uninfected immune cells )(T , infected immune cells )(
iT  and the HIV          











   (12b) 
uVkT
dt
dV i  . (12c) 
 
 
Eqn. (12a) gives the change in the uninfected immune cell population. The first and 
second terms of this equation represent source and death terms where uninfected cells are 
…
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replenished at a constant rate,  , and die at a rate, d , proportional to its population. The 
third term is a loss due to infection term where virions encounter uninfected cells and 
infect them at a rate   proportional to both populations.  
 
Eqn. (12b) gives the change in the infected immune cell population. The first term is 
carried over from eqn. (12a) and represents an increase in infected cells due to infection. 
The second term represents the natural death of infected cells which die at a rate a  
proportional to its population. 
 
Eqn. (12c) gives the change in the HIV virion population. The first term is a source term 
in which virions are produced from infected cells at a rate k  proportional to the infected 
cell population. The second term is a natural death term where virions die at a rate u  
proportional to their population. 
 
A diagrammatic illustration [100] of the dynamics that are modelled by eqns.             
(12a) – (12c) is shown in Figure 11. 
 
 
Figure 11: Schematic illustration of the basic HIV- 
immune system model [100]. 
 
 
6.1.1. Conditions for Infection  
 
We now consider the mechanism by which infection occurs as modelled by the basic HIV 
model. When a small amount of HIV virions is added to the system, the virions infect the 
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uninfected cells, thus producing newly infected cells, which in turn produce new virions. 
This process can repeat itself leading to a chain reaction. The chain reaction can either go 
one of two ways, it can either be self-sustaining or it can die out. Whether it is successful 
in sustaining itself depends on a quantity called the basic reproductive                         
ratio )( 0R  [10, 11, 100]. The basic reproductive ratio is defined as the average number of 
secondary infected cells generated by a single infected cell at the beginning of an 
infection.  
 





0 . 0R  can be understood in an 
intuitive manner [101], as illustrated in Figure 12, by noting that 
a
k
 is the burst size, 
which gives the total number of virions produced from any one infected cell, 
d

 is the           
preinfection (  0iT and 0V ) equilibrium density of uninfected cells,   is the rate of 
infection per unit time and 
u
1
 is the average life-span of an HIV virion [10, 101].  
 
 




If 10 R , then on average at the start of infection any one infected cell generates less 
than one newly infected cell, which means the infection is not able to sustain itself and 
eventually dies out, with the uninfected cell population converging to its preinfection             
… 
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equilibrium value, given by eqn. 13(a). Conversely, if 10 R , then on average at the 
beginning of infection any one infected cell generates more then one newly infected cell, 
which means the infection is able to take off and after some time converges to its 















T i 1,1, 00
0
 . (13b) 
 
 
6.1.2. Simulations  
 
One can investigate the dynamical behaviour of the basic HIV model shown in Figure 13, 
where two simulations were carried out, one for 10 R , and another for 10 R .      
Figure 13 serves to confirm, respectively, that, when 10 R , the infection cannot sustain 
itself and soon dies out; and, when 10 R , the infection takes off and there is an 
exponential increase in viral load.  
 
Parameter values used in the simulation are 510 , 0.1d , 0.5a , 100k , 5u , 







oT  and        
1000 V  [101]. To satisfy 10 R  put 
8102  .  
 
When 10 R , one observes from the graph of the HIV virion population shown in   
Figure 13a and the graph of the infected cell population shown in Figure 13b that the 
infection is unable to sustain itself and dies off. In addition there is no discernable change 
in the uninfected cell population shown in Figure 13c. One notes that the simulated 
equilibrium values are in agreement with the values predicted by eqn. 13 (a). 
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Column I: R0=0.8 
 
Column II: R0=8 
a. 














































































































Figure 13: Simulations of the basic HIV model for two regimes of 0R  values: Column I, 10 R , 
and Column II, 10 R . Column I shows that HIV infection dies out when 10 R  and Column II 
shows that HIV infection takes off when 10 R .   
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When 10 R , one finds that at the start of infection there is an exponential increase in the 
levels of the HIV virion and infected cell populations, as seen in Figures 13d and 13e 
respectively, where each population peaks before subsequently levelling off to their 
equilibrium values. The uninfected cell population initially stays approximately constant 
before it declines to a minimum value and subsequently recovers to its equilibrium value, 
see Figure 13f. The qualitative dynamics portrayed by the basic HIV-immune system 
model are typical of primary HIV infection [74, 86, 101, 127] in HIV-positive 
individuals. At very least the basic HIV model is able to give one some idea of the type of 
qualitative dynamics one would expect during primary HIV infection. The equilibrium 
values of ,1025.1
5T  ,1075.1
5iT  and 6105.3 V  obtained by the numerical 
simulations confirm the predictions of eqn. 13(b).  
 
 
6.1.3. Analysis and Implications  
 
During primary HIV infection it has been suggested that the observed decline in viral 
load of up to 2-3 orders of magnitude after the viral load peaks is due to antibody and 
cellular immune responses [30, 81, 101, 105]. Intriguingly, although the basic HIV model 
does not include the specific involvement of an immune response, the model does reflect 
the decline in viral load and infected cells during persistent infection. Witten and 
Perelson [141] illustrated that in terms of the basic HIV model one can argue that, if the 
immune response played a role in lowering the level of viral load, its contribution would 
need to be small or constant. To illustrate their point they modelled the rate of death of 
infected cells a  as having two components by expressing it as Xaaa X 0 . The two 
components, 0a  and Xa X , that contribute to the death rate are each respectively due to 
viral cytopathic effects and cytotoxic T-lymphocyte (CTL) immune responses [12, 107]. 
In the cytotoxic T-lymphocyte immune response term X  denotes CTL and Xa  denotes 
the contribution to the rate of death of infected cells per CTL. From Xaaa X 0 , 
which gives the total rate of death of infected cells, one sees that in order for a  to be     
… 
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approximately constant either Xa X  is small relative to 0a  or is itself approximately 
constant. During chronic infection one could easily envisage a constant immune 
response; however, during primary infection a CTL immune response is generated and 
correlates temporally with the decline in viremia [12, 81]. Hence it is surprising that the 
basic HIV model which has a constant death rate of infected cells can account for 
dynamics displayed in primary HIV infection. The reason that the basic HIV model 
displays a decline in viral load from its peak is due to a target cell limitation implying that 
there is a running out of susceptible cells [108].  
 
For most HIV infected individuals, following the resolution of the acute primary HIV 
infection, viral load reaches a set-point and becomes relatively stable over a period of 
time. A set-point is achieved due to the fact that a balance is reached between the viral 
replication rate and the viral clearance rate. The level at which the set-point equilibrates 
after primary acute HIV infection is important since an individual with a higher set-point 
viral load has a greater risk of more rapidly progressing towards AIDS [92].  
 
 
6.2. Basic HIV Model with Treatment 
 
By modifying the basic HIV-immune system model one is able to include the effects of   
antiretroviral therapy into the model. The modification is performed by noting that 
reverse transcriptase ( RT ) inhibitors block the ability of HIV to infect a cell 
successfully. Protease inhibitors ( PI ) cause the production of noninfectious viral 
particles ( niV ).  
 
Applying these therapeutic mechanisms to the existing structure of the basic HIV-






 )1(   (14a) 





















  . (14d) 
 
 
where RT  and PI  represent the respective efficacies of the reverse transcriptase and 
protease inhibitors. For a perfect inhibitor, one that is a 100% effective, 1 . The action 
of the protease inhibitor serves to divide the HIV virion population into infectious and          
noninfectious viral particles. The levels of infectious and noninfectious HIV virion 
populations are denoted by iV  and niV  respectively. The total number of free virions is 
given as nii VVV  .  
 
Perelson et al [107] were able to show that, if a 100% effective protease inhibitor 
(initially drug resistance effects are not discernable) is administered to an HIV-positive 
individual at steady state with viral load 0V  and one assumes that over the period of 
interest the uninfected cell population (T ) remains constant, the viral load decay obeys 















utVtV . (15) 
 
 
By using nonlinear least squares regression to fit eqn. (15) to clinical data, estimates were 
obtained for the parameters a  and u . Estimates for the average life-time of an infected 
cell and the average life-time of a free virus particle are then obtained by noting that these 






 respectively. One can then proceed to calculate the half-life 
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1   
respectively. Moreover estimates of the total virion production and clearance rates can be 
obtained by noting that at steady state the production rate of virions must equal its 
clearance rate Vu , c.f. eqn. (12c). Thus it is possible to estimate virion production rates 
by using the previously obtained estimate of u  and the pretreatment viral      
concentration 0V . 
 
Once the necessary mathematical underpinning had been developed, the researchers then 
obtained clinical date from a group of five infected individuals who were administered 
Ritonavir, a potent protease inhibitor. The total plasma concentration and fluid volume of 
each individual was estimated on the basis of the individual’s body weight. The total 
daily virion production and clearance rates were then obtained using the previously 
outlined methods and found to be in the range 9104.0   to 9101.32   (mean 9103.10  ) 
virions per day being released into the extracellular fluid. It was noted that this estimate is 
a minimum estimate since virions that are not released into the extracellular fluid are not 
included in the estimate.  
 
This work demonstrates that the latent stage of HIV disease progression is not a static 
process. The model reveals the enormous turn-over rates of around 1010  HIV virions per 
day in the human body. Clearly there are major dynamical processes that are taking place 
in the background even though one might not have thought this to be the case since the 
levels of HIV prognostic markers seem to be relatively stable. This is a good example of 
how mathematical modelling can be utilised to increase our understanding of the 
biological processes that occur during HIV disease progression.  
 
 
6.3. Late versus Early Treatment  
 
Before the advent of combination therapy, such as HAART, there has been much debate 
with regards to the particular stage of disease progression at which AZT monotherapy      
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should be initiated. A literature review revealed that there seemed to be conflicting 
results, with some advocating early treatment (200-500 CD4
+
 T cells per mm
3 
of       
blood) [45, 60, 84, 120, 136], whereas others advocate late treatment (< 200 CD4
+
 T cells 
per mm
3
 of blood) [28, 64]. In order to seek clarity on this matter a mathematical model 
was developed by Kirschner and Webb [76]. Results from their simulations agree well 
with the Concorde Study [24] which was set up to investigate the relative merits of late 
versus early treatment of HIV with AZT monotherapy. The study, which was conducted 
by the British Medical Research Council and the French National AIDS Research 
Agency, examined 1749 asymptomatic HIV-positive people in the United Kingdom, 
Ireland, and France. The Concorde study has shown that early treatment of HIV patients 
with AZT monotherapy does not necessarily produce a more favourable                   
prognosis [24, 76]. 
 
 
6.3.1. Model Development  
 
Developing mathematical models like the Kirschner-Webb model are important in order 
to gain a qualitative understanding of AIDS chemotherapy. One can test different 
strategies of drug administration in terms of timing, dose and frequency with such 
models. The qualitative results that the model yields would be able to help us gain insight 
into optimising the drug administration regime one would use in a clinical setting. 
 
The Kirschner-Webb model was developed from the known mechanisms of interaction of 
HIV and the immune system, including the effects of AZT monotherapy. The population 
dynamics that the model simulates occur in a single compartment. This compartment is 
taken to be the peripheral blood. By modelling a single compartment one ensures that 
there are no flows from outside compartments and that the equations are scaled 
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Table 1: Variables and Parameters 
 
Dependent Variables Initial values 
T  Uninfected T cell population
  
 -3mm 1000  
iT  Infected T cell population 
-3mm 0.0  
V  HIV virion population  -3-3 mm 101.0  
 
Parameters and Constants Values 
)(ts  Source of new T cells
 












1c  Half saturation constant for T cell growth  
-3mm 1  
 
1s  Source of new T cell in absence of infection 
-1-3 day mm 10  
 
2s  Rate of change in T cell supply  
-1-3 day mm 10  
 
T  Death rate of uninfected T cell population 
-1day 0.02  
 
iT
  Death rate of infected T cell population -1day 0.24  
 
Vk  Rate T cells become infected by free virus  
-13-5 day mm 102.4   
 
Tk  Rate CD8
+
 T cells kill virus  -13-4 day mm 107.4   
 
r  Maximal proliferation of T cell population  -1day 0.01  
 
N  Number of free viral particles produced by  
bursting infected cells  
 
1000 
C  Half saturation constant of the proliferation process -3mm 100  
 
b  Half saturation constant of the external viral source -3mm 10  
 
Vg  Growth rate of the external viral source  
other than T cells (e.g. macrophages)  
-1day 20-5  
 
 
















































 . (16c) 
 
 
Eqn. (16a) describes the change in the T cell population. The equation’s first term is a 
source term for new T cells from the thymus. HIV can infect thymocytes (T cell 
precursors); therefore, the source term is represented as a decreasing function of viral 











 , has been shown to be a 
good first approximation [77]. The next term is a natural loss term due to the finite      
life-span of T cells. This is followed by a T cell stimulation term representing the 
stimulation of T cells to proliferate in the presence of virus. Since T cells do not grow 
without bound, a saturation term of the Michaelis-Menten type, which is believed to 
encompass the desired effects [76], was used to represent this process. The final term 
represents the loss of T cells due to infection by HIV.  
 
Eqn. (16b) describes the change in the infected T cell population. The first term, which is 
a gain due to infection term, carries over from the loss term in eqn. (16a). Next there is a 
loss term due to the finite life-span of infected T cells. This is followed by a Michaelis-
Menten type loss term due to cytolysis of infected cells during the proliferation process. 
 
Eqn. (16c) describes the change in the HIV virion population. The first term, which is a 
gain term, carries over from the cytolysis loss term in eqn. (16b) with factor N  in front. 
The factor N  represents the burst size, that is, the average number of virions produced 
from a single infected cell. This is followed by a loss term due to specific immune 
response, namely CD8
+ 
T cells killing the virus. The final term is a gain term of the 
Michaelis-Menten type which represents growth of virus from other infected cells, for 
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example, macrophages and thymocytes. This term also implicitly accounts for the natural 
death of virions. If an explicit natural death term, such as VV , is included, an 
additional steady state arises which has negative values making it invalid. Furthermore 
the virions that die naturally do not affect the dynamics of the model since they do not 









6.3.2. Model Simulation  
 
Simulations were run for different values of the external viral source growth rate Vg . It 
was observed that by changing the values of Vg  one could simulate the different stages of 
disease progression. Primary infection and the infected steady state is shown in Figures 
15a – 15c with 5Vg . The progression towards AIDS is shown in Figures 15d – 15f 
with 20Vg . Finally by gradually increasing the external viral source from 5Vg  to 
20Vg  the complete course of HIV infection is shown in Figures 15g – 15i. 
 





Column I: 5g V   Column II: 20g V   Column III: Vg  increased 
from 5g V   to 20g V   
 
a. 

















































































































































































































Figure 15: Simulations of the Kirschner-Webb model for three different regimes of Vg . When 
5Vg , Column I simulates the HIV infected steady state. When 20Vg , Column II simulates 
the progression to AIDS. By increasing Vg  over time from 5Vg  to 20Vg , Colunm III 
simulates the entire course of HIV infection. 
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Figures 15a – 15c, which simulate the primary and latent stage of HIV infection, show 
numerical solutions of the model for 5Vg . The model does to some extent display 
typical qualitative behaviour associated with primary and latent infections. For primary 
infection there is initially an increase in virion and infected cell count while the T cell 
count experiences a decline. Thereafter all populations settle to set-point values as 
expected during the latent stage of the disease. The model, however, does not display the 
initial spike in viral load that one would associate with primary infection, as some other 
models that are reviewed below do.  
 
In Figures 15d – 15f, which simulate the progression to AIDS, the external viral source 
growth rate is increased to 20Vg . This increase may be due to factors such as 
mutations or increased efficiency in viral production. During this phase one typically 
finds that there is a steep increase in the viral load accompanied by equally dramatic 
decrease in the T cell population, just as the simulations of the model suggest. 
 
Figures 15g – 15i simulate the entire course of HIV infection by increasing the external 
viral source growth rate from 5Vg  to 20Vg over time. Note that the steep decrease 
in the T cell population and steep increase in the viral load at day 1500, signaling the 
onset of AIDS, occurs over the period of a year.  
 
 
6.3.3. Bifurcation Analysis  
 
We have seen that the external viral source growth rate plays an important role in the 
dynamics of the model. By increasing Vg  the model is able to simulate the collapse of the 
immune system, representing the onset of AIDS. Figure 15a shows that for 5Vg  the 
viral load stabilises to a positive constant; however, Figure 15d shows that for 20Vg  
the viral load grows linearly without bound. Clearly a qualitative change takes place in 
the dynamics of the model as Vg  is increased. In order to understand the changes that 
occur to the qualitative behaviour of the system, one can do a bifurcation analysis of the 
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system. We begin our analysis by examining the steady state solutions for the system. For 












in eqn. (16a), is approximated by a constant denoted by s . In addition let steady state 
values be denoted by an over-bar. Putting eqns. (16a) – (16c) equal to zero and 
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Clearly eqn. (20) entails solving a cubic for V  in terms of the parameter values given in 
Table 1. Nevertheless the bifurcation analysis performed by varying Vg  in Figures         
16a – 16c reveals that at most there are only two real steady state values of V  for the 
given parameter values. We have specifically chosen to vary Vg  since this parameter 
may vary between different individuals and also between the different stages in disease 
progression. By plotting bifurcation diagrams for each of the model’s populations, where 
Vg  is varied between 5 and 20 as it had been in the simulations shown in Figure 15, one 
is able to gauge the extent of the qualitative changes that the system undergoes. 
 
a. 
































































































Figure 16: Bifurcation diagrams of the Kirschner-Webb model created by varying Vg  from 5 to 
20. The diagram shows that the system has at most two real-valued solutions, with one 
being stable and the other being unstable. A saddle-node bifurcation occurs at 8.15Vg . 
 
HIV-Immune System Models 
 58 
One sees from Figure 16 that a saddle-node bifurcation (limit point) occurs at about 
8.15Vg . It is at this point that the two steady state solutions of the system, one stable 
and the other unstable merge into a single solution.  
 
One is now in the position to plot a two-parameter bifurcation diagram by varying N , the 
number of free viral particles produced by bursting infected cells. This two-parameter 
bifurcation diagram gives the Vg  and N  values at which a saddle-node bifurcation takes 
place. The reason for varying N  in addition to Vg  is that N  is also an important 
parameter which governs the qualitative behaviour of the system and, like Vg , N  has a 
fair amount of uncertainty associated with it.  
 














Figure 17: Two-parameter bifurcation diagram for the Kirschner-Webb model with the growth 
rate of external viral source Vg  vs. the number of virions produced from cell bursting N . In 
region i positive steady-state equilibrium values for all three populations are attained, 
signifying chronic HIV infection. In region ii the viral load grows linearly without bound, 
signaling the onset of AIDS.     
 
 
The qualitative behaviour of the system for the regions i and ii are described as follows. 
In region i positive steady-state values for all three populations are attained when they 
asymptotically converge to the single stable node of the system. This behaviour is 
exhibited in Figures 16a – 16c for values of 8.15Vg , where the system converges to 
the steady state values denoted by the blue portion of the graphs. In region ii the T cell 
population converges to 0, the infected T cell population converges to a positive constant; 
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however, the HIV population grows linearly without bound. This type of qualitative 
behaviour signifies the onset of AIDS and is consistent with the Center for Disease 
Control’s Definition for AIDS and AIDS-related complexes [76]. The simulations shown 
in Figures 15d – 15f demonstrate this behaviour. The fact that the HIV population grows 
without bound in region ii means that this regions does not attain any steady state 
solutions. This behaviour can be seen in Figures 16a – 16c  for values of 8.15Vg , 
where branches for the steady state solutions of the system do not extend beyond 
8.15Vg .   
 
 
6.3.4. Finding R0 
 
All simulations of the model that have been run thus far have only been of HIV infections 
that were able to sustain themselves. This is indicative of basic reproductive ratios that 
are greater than 1 ( 10 R ). One is able to find the analytical value of 0R  by doing a 
linearised stability analysis of the uninfected steady state. A threshold condition for the 
uninfected steady state becoming unstable and the infected steady state assuming stability 
yields the analytical value of 0R . The uninfected steady state has 0 populations for both 
HIV and infected T cells. Using eqns. (16a) – (16c) to solve for the uninfected steady 








T  and 0V . (21) 
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The three eigenvalues of the system are 
 
T 1 , iT 2  and Tkbg TV 3 .   (24) 
 
 
For the system to be locally asymptotically stable in the uninfected steady state, one 
requires that the eigenvalues of eqn. (24) be all negative. This is clearly the case for the 
first two; however, in order for the third eigenvalue to be negative, one requires 
 
0 Tkbg TV  or equivalently 1bkTg TV .    (25) 
 
 
If 1bkTg TV , then the uninfected steady state loses stability and the infected steady 
state becomes stable, which implies that 
 
bkTgR TV0 . (26) 
 
 
By substituting TsT   and using parameter values of Table 1 in 0R , one finds that, if 
7.3Vg , we have 10 R  and, when 7.3Vg , we have 10 R . The Bifurcation 
diagrams created by varying Vg  between 0 and 5 shown in Figures 18a – 18c confirm 
that when 7.3Vg , a sustainable HIV infection is achieved, that is, the blue branches of 
the HIV virion and infected cell populations are both positive thereby indicating positive 
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steady-state solutions for these populations. However, when 7.3Vg , the blue branches 
of the HIV virion and infected cell populations are both zero which is indicative of an 
uninfected steady state. 
 
a. 


































































































Figure 18: Bifurcation diagram of Kirschner-Webb model created by varying Vg  from 0 to 5. 
The diagram confirms that, when 7.3Vg , we have 10 R  and the system converges to 
the uninfected steady state. Conversely, when 7.3Vg , we have 10 R and the system 
converges to an HIV infected steady state. 
 
 
6.3.5. Model with AZT Monotherapy  
 
Using the Kirschner-Webb model one is able to obtain guidelines to the question that was 
initially posed at the beginning of the section, that is, is early treatment of HIV with AZT 
monotherapy more beneficial than late treatment? In order for the model to tackle this 
question it needs to be slightly modified to allow for AZT monotherapy. We recall that 
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AZT is a reverse transcriptase inhibitor and it therefore blocks the ability of HIV to 
successfully infect a cell. Thus the )()( tVtTkV  term in eqns. (16a) and (16b) is modified 
by introducing a factor )1( RT  in front of the term. As was the case in eqns. (14a) and 
(14b), RT  values can range from 0 to 1 and represents the efficacy of AZT to inhibit the 
ability of HIV to successfully infect a cell. 1RT  represents a perfect inhibitor. The 
















































 . (27c) 
 
Suppose that for a patient taking AZT for the first time it is initially 100% effective, that 
is, the virus had not been exposed to the drug long enough for the effects of resistance to 
be discernable. In addition assume that the patient takes the drug continuously so that 
before the effects of the drug wears off the patient is administered another dose of         
the drug.  
 
Comparing simulation results for early and late treatment shown in Figure 19, one finds 
that during the late treatment regime the individual’s T cell count remains elevated for a 
longer period of time, in excess of 100 days relative to the early treatment regime, before 
it starts to display signs of collapsing. This comparison is clearly shown in Figure 20 by 
superimposing the T cell counts of each of the regimes. The results of the simulation 
therefore do not advocate early treatment over late treatment and is thus in good 
agreement with the findings of the Concorde study [24]. Also notable was the model’s 
ability to demonstrate the importance of HIV chemotherapy by showing that only a 
minimal amount of treatment was necessary to perturb the system from collapsing 
towards AIDS. 
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Column I: Early continuous therapy Column II: Late continuous therapy 
 
a. 






































































































































Figure 19: Simulations of early continuous and late continuous AZT monotherapy treatment. 
Early continuous treatment is simulated by administering therapy for 250 days beginning on the 
100
th
 day after the immune system starts collapsing towards AIDS. Late continuous treatment is 
simulated by administering therapy for 250 days beginning on the 200
th
 day after the immune 
system starts collapsing towards AIDS. Administering treatment for only 250 days is done merely 
for simulation purposes and has no medical significance as such. Initial conditions and parameter 
values used to run the simulations are given in Table 1 with Vg =20. 
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Figure 20: Superimposing T cell counts for early and late treatment regimes. For late treatment, 
T cell count remains elevated for a longer period of time, in excess of 100 days relative to the 






HIV-TB Coinfection Model  
 
 
One of the central themes of this dissertation is to study the interaction between HIV, TB 
and the immune system of the coinfected individual. Such a study is very relevant in the 
context of Sub-Saharan Africa, where there are high rates of coinfection exacerbated by 
the fact that each infection promotes disease progression in the other thereby increasing 
morbidity and mortality, c.f. section 4.3.  
 
 
7.1. Model Development   
 
Due to the endemic nature of HIV-TB coinfection in Sub-Saharan Africa it would be 
beneficial to have models that study the interaction of HIV, TB and the human immune 
system in order to gain insights into the dynamics of these interactions. Nevertheless, 
after a literature search had been conducted, only one such model was found. The model, 
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Table 2: Variables and Parameters 
 
Dependent Variables Initial values 
T  Uninfected T cell population
  
 -3mm 1500  
M  Macrophage population -3mm 85  
V  HIV virion population  -3-3 mm 101.0  
bT  M. tuberculosis population  
-3mm 1.0  
 
Parameters and Constants Values 
T  Death rate of uninfected T cell population  
-1day 0.007  
M  Death rate of macrophage population 
-1day 0.003  
V  Death rate of HIV virion population 
-1day 2.4  
bT
 Death rate of M. tuberculosis population -1day 0.5  
1k  Rate CD4
+ 
T cells become infected by free virus -13-5 day mm 102.4  
2k  Rate macrophages become infected by free virus 
-13-6 day mm 102.0  
Vg  Rate macrophages produce virus  
-13-6 day mm 101.0  
3k  Rate CD8
+ 
T cells kill virus -13-4 day mm 107.4  
4k  Rate macrophages kill virus 
-13-4 day mm 107.4  
5k  Rate T cells clear M. tuberculosis 
-13 day mm 0.5  
6k  Rate macrophages clear M. tuberculosis  
-13 day mm 0.5  
Tr  Maximal proliferation of the T cell population  
-1day 0.02  
bT
r  Maximal proliferation of the M. tuberculosis population -1day 1.0  
Mr  Recruitment rate of macrophage population  
-1-7 day 102.5  
1N  Number of free virus produced by infected T cells 100 – 1000 
2N  Number of free virus produced by macrophages 100 – 1000 
C  Half saturation constant for the proliferation process  mm 1000 -3  
K  Carrying capacity for the M. tuberculosis population   mm 1000 -3  
0M  Equilibrium value for the macrophage population   mm 100
-3
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Once again the model dynamics are assumed to take in a single compartment, where this 
time the compartment is taken to be the lymph tissue. Model parameters for HIV in   
Table 2 are obtained from peripheral blood data; however, the lymph and periphery are 
generally assumed to be in parallel [62]. The model uses four variables to describe the 
different population dynamics. )(tT  represents the armed CD4+ and CD8+ T cell 
populations at time t  in days, )(tM  represents the macrophage population, )(tV  
represents the HIV virion population and )(tTb  represents the M. tuberculosis population. 
The model is explained as follows.  
 
Eqn. (28a) represents the change in the T cell population. This equation models the 
change in the T cell population in a manner analogous to eqn. (16a), c.f. Section 6.3.1. for 
a term-by-term explanation, with the only difference being in the third term where T cells 
are stimulated to proliferate by the presence of both virus and bacteria instead of        
virus alone. 
 
Eqn. (28b) represents the change in the macrophage population. The inclusion of an 
equation representing macrophagic dynamics is important for the following reasons. 
Macrophages play an important role in the pathogenesis of TB [44], infected 
macrophages act as a reservoir for HIV by slowly budding new viral                     
particles [54, 104] and infected macrophages can infect CD4
+
 cells through the 
presentation of antigen [2, 85]. The first term of eqn. (28b) represents the birth-death 
process for macrophages. This is followed by a term representing the loss of 
macrophages due to infection of by HIV virions. The final term represents the increase in 
the population of macrophages due to macrophagic recruitment and stimulation in 
response to the presence of pathogen.   
 
We note from eqn. (28a) and (28b) that although macrophages and T cells are both 
immune system cells their production are not modelled as parallel processes. The 
production of T cells is modelled via a Michaelis-Menten type response term which 
depends on the antigenic stimulation due to both HIV and TB and has a single 
recruitment rate, i.e. Tr . Modelling T cell production in this way is believed to encompass 
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the desired effects [76]. Macrophagic production, on the other hand, is bilinear with the 
antigenic stimulation due to HIV being distinct from that due to TB with each having a 
different rate of production, i.e. 1Mr  and 
2
Mr  respectively. The production of macrophages 
is modelled in this way since macrophagic production due to antigenic stimulation is not 
as yet fully understood. Therefore by using a bilinear type response term one allows for 
the possibility that production rates due to antigenic stimulation by HIV could well be 
different from that due to TB. 
 
Eqn. (28c) represents the change in the HIV virion population. The first term is a virion 
source term. The first part of the first term represents the increase in virion population 
due to virion production by infected T cells. It carries over from the loss due to infection 
term of eqn. (28a) with an additional factor 1N  in front to account for the virion burst 
size. The term’s second part represents the increase in virion population due to the virion 
production by infected macrophages. Similarly it too is a carry over term. It carries over 
from the macrophage loss due to infection term of eqn. (28b) with an additional factor 
2N  for the macrophage burst size. Observe that, when this term carries over, the 
parameter 2k  changes to Vg . This is done because macrophage infection is not well 
understood; therefore it is necessary to allow for the possibility that the virion production 
rate ( Vg ) could be different than the virion infection rate ( 2k ). The second term of the 
equation is a loss term. It represents a decline in virion population due to immune 
clearance in that CD8
+
 T cells and macrophages clear or kill HIV virions and infected 
cells. The final term of the equation represents the clearance of viral particles due to 
death since HIV virions have a finite life-span. 
 
The final equation of the model, eqn. (28d), represents the change in the M. tuberculosis 
population. The first term of the equation represents bacterial growth in the form of a 
logistic growth term with carrying capacity denoted by the constant K . Next there is a 
clearance term due to death of bacilli as a result of M. tuberculosis having a finite       
life-span. The final term represents the immune clearance of M. tuberculosis by T cells 
and macrophages. 
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The aim of the immune system-HIV-TB model is to capture the dynamics that take place 
during the primary infection and asymptomatic period of disease progression, that is to 
say, the simulation is run until it reaches its steady state, where the steady-state represents 
the asymptomatic stage. There are four different permutations of steady states that the 
model can exhibit. These are the uninfected steady-state (no HIV or TB infection),    
HIV-infected steady-state (only HIV infection), TB-infected steady-state (only TB 
infection), and the coinfected steady-state (both HIV and TB infection). The simulation is 
run for each in turn. 
 
 
7.2. Simulations  
 
7.2.1. Uninfected Steady-State  
 
Setting HIV and TB to zero, Figure 21 shows simulations of the uninfected state. 
Numerical solutions of the T cell and macrophage populations are seen to converge to 
positive steady-state values. One can easily verify from eqns. (28a) and (28b) that in the 
absence of infection steady-state solutions for T cells and macrophages are TTS  and 
0M  respectively. The simulation is started with initial conditions slightly away from the 













































Figure 21: Simulations of the uninfected state (no HIV or TB infection). The model is seen to 
converge to its steady-state values, which when solved analytically are given by TTS  for the 
T cell population and 0M  for the macrophage population. 
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7.2.2. HIV Infected Steady-State  
 
Setting TB to zero, the population graphs of Figure 22 for the numerical solution of the 
HIV infected steady-state shows that the model is able to approximate the primary and 
asymptomatic stage (quasi steady-state stage) of HIV infection. In a clinical setting 
during initial infection we find a large spike in viral load that is short lived; thereafter the 
immune system brings the viral load down and it settles to a quasi steady-state. Typically 




 virons per mm
3
. Once viral load 
stabilises, there is great variation amongst individuals as to what level it stabilises; 
nevertheless it usually settles in the range 10 to 100 virons per mm
3
 and subsequently 
increases with disease progression. On inspection of Figure 22a one finds that the HIV 
population graph displays the qualitative and quantitative dynamics described above. The 
spike of the viral load graph peaks at 4108.5  virions per mm
3
 and its set-point value is 
88 virions per mm
3
. Similarly, the qualitative behaviour of the T cell count and 
macrophage population, Figures 22b and 22c respectively, are also as one would expect 
them to be in that at the beginning there is a decline in the T cell count and macrophage 
population due to loss from initial HIV infection; however, subsequently to this there is 
an increase in each population as a result of antigenic stimulation of an immune response 






























































Figure 22: Simulations of the HIV infected state (HIV but no TB infection). After initial HIV 
infection there is a short-lived spike in the viral load; thereafter it settles down to its steady-state 
value. The T cell and macrophage populations initially experience a decline due to the HIV 
infection, but thereafter they experience an increase due to antigenic stimulation of the immune 
system before settling down the their set-point values. These dynamics, as displayed by the 
model, are typical of the qualitative behaviour of HIV infection before the onset of the immune 
system collapse. 
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7.2.3. TB Infected Steady-State  
 
Setting HIV to zero, we find that the population graphs of Figure 23 for the TB infected 
state show that the T cell, macrophage, and M. Tuberculosis populations all progress to 
positive steady-state values. The TB bacteria population’s positive steady-state value is 
indicative of chronic TB infection. 
 


























Figure 23: Simulations of the TB infected state (TB but no HIV infection). The TB bacteria 
population progresses to a set-point value of 115 TB bacteria per mm
3
, thereby establishing a 
chronic TB infection.   
 
 
7.2.4. Coinfected Steady-State  
 
Simulations for coinfection are shown in Figure 24. When both diseases are present, one 
can clearly see the adverse effects that TB infection has on an HIV-positive person. This 
is shown by the plot of the HIV population in Figure 24a where the set-point value is 
approximately 250 virons per mm
3
, as compared with 88 virons per mm
3
 seen in the 
graph of HIV alone in Figure 22a. As was noted in section 4.3, an increased viral load is a 
very worrying sign indeed as it is used as a prognostic indicator for the speed of the onset 
of AIDS. The increase in viral load shown by the model simulations are due to an 
increase in susceptible cells (T cells and macrophages) which HIV virions can infect. As 
was previously discussed, a limitation in susceptible cells does limit the set-point of the 
viral load [108]. Thus an increase in susceptible cells increases the set-point of the viral 
load. The increase in T cells and macrophages are a result of increased antigenic 
stimulation from both the HIV and TB infections, as opposed to just one disease alone.  
…    
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However, in a clinical setting the increase in viral load during coinfection might also be 
due to the overworked immune system having to simultaneously fight off two diseases 
instead of just HIV. 
 
a. 
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Figure 24: Simulations of the coinfected state (both HIV and TB infection). Coinfection with 






Chapter 8  
 
Modelling Coinfection Treatment 
 
 
In South Africa HIV-positive individuals tend only to be diagnosed after the 
asymptomatic period of HIV infection when the immune system is collapsing and the 
individual is most likely to be coinfected with TB. Generally medical practitioners do not 
prescribe both antiretroviral and TB treatment concurrently. Antiretrovirals on their own 
have significant side-effects. Combining antiretroviral treatment with TB treatment 
escalates these adverse side-effects due to the overlapping toxicity profiles of both drug 
regimes and the large number of pills required to treat for each disease [35]. Moerover, 
drug-drug interactions could also lead to suboptimal therapeutic results [16]. Due to the 
severity of the side effects of the combined medications, strict adherence to the drug 
intake regime by coinfected individuals might be compromised. This could lead to grave 
implications for both diseases. Drug resistant strains of TB and HIV could develop and 
the rate of HIV disease progression would be significantly increased, signaling the earlier 
onset of AIDS.  
 
The Centre for the AIDS Programme of Research in South Africa (CAPRISA) has 
commenced the START trial (STarting Anti-Retroviral Therapy). These trials are 
designed to resolve the question, when would the optimal point in time be to commence 
antiretroviral treatment in coinfected individuals? Researchers are still uncertain as to 
whether the best time to start antiretroviral treatment for HIV-TB coinfected individuals 
is at the beginning, the peak, or after the completion of the TB treatment phase. Clearly 
for reasons previously outlined one would hope to treat for HIV after completing TB 
treatment; however, this treatment strategy might not always be feasible. When disease 
progression for both infections is in advanced stages, death could result from either one 
of the diseases. One hopes that at the completion of the START trials there are clear 
guidelines established on how to treat such situations. 
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8.1. Model Development 
 
In addition to clinical trials, by developing a mathematical model for HIV-TB               
coinfection which includes treatment, one can obtain clues as to what the most effective 
treatment strategies are likely to be. The development of such a model was undertaken 
during this dissertation. It was noted that there are certain desirable features that the 
model should possess. It should be able to simulate HIV infection and TB infection 
independently, as well as being able to simulate coinfection. The model should be able to 
simulate the treatment of HIV by both treatment mechanisms, that is protease inhibition 
and reverse transcriptase inhibition. We have seen that the coinfection model of     
Section 7.1 was able to simulate infection with each disease separately, as well as         
coinfection, and the HIV treatment models of Sections 6.2 and 6.3.5 incorporated features 
for modelling treatment with reverse transcriptase and protease inhibitors. Thus it would 
be prudent to combine the desirable mathematical structures of these models when 
constructing a model to stimulate the treatment of coinfection. In addition to the above 
we need to add TB treatment mechanisms, in terms of the bacteriostatic and bactericidal 
action of TB drugs. A new coinfection model was developed to successfully combine the 
desirable features of the previous models. This model has the ability of being easily 
modified to accept HIV and TB treatment (as we show below). Firstly we present the 
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We once again assume that the model dynamics take place in a single compartment, the 
lymph tissue. For the sake of continuity the variables used to describe the six populations 
employ the same notation as the previous models. )(tT  represents the T cell population at 
time t  in days, )(tT
i  represents the HIV infected T cell population, )(tM  represents the 
macrophage population, )(tM
i
 represents the HIV infected macrophage population, 
)(tV  represents the HIV virion population, and )(tTb  represents the M. tuberculosis 
population. Model parameters are listed in Tables 1 and 2. The model is described           
as follows. 
 
Eqns. (29a), (29c), and (29f) use the mathematical structure found in the coinfection 
model of Section 7.1, where term-by-term descriptions for each of the equations are 
given. Similarly eqn. (29b) can be found in the HIV model of Section 6.3.1.  
 
Eqn. (29d) represents the change in the infected macrophage population. Its first term, 
which comes from the macrophagic loss due to HIV infection term in eqn. (29c), is 
carried over as a source term. The second term represents the natural death of 
macrophages due to finite life-span.  
 
Eqn. (29e) gives the change in the HIV virion population. The first term is a source term 
that represents budding of virions from infected T cells with the rate that infected T cells 
produce virus denoted by VTg  and the burst size denoted by N . The second term comes 
from eqn. (16c) Section 6.3.1. The third is a source term that represents virion budding 
from infected macrophages with the rate that infected macrophages produce virus 
denoted by Vg  and the burst size denoted by 2N . The fourth and fifth terms come from 
eqn. (28c) Section 7.1.  
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From the discussion above one notes that this new model has been developed by using 
many of the structures found in models that were reviewed earlier in this dissertation. The 
sole purpose of developing a new model in this way is to allow it to accept treatment for 
HIV and TB so that the different treatment scenarios that arise when treating for HIV-TB 
coinfection can be tested. It is shown below that this model can easily facilitate the 
therapeutic mechanisms used to simulate both HIV and TB treatment.  
 
However, before any treatment strategies are tested one has firstly to ensure that the 
model is able to simulate disease progression accurately. The model is evaluated by 
comparing its results to the published models that were presented earlier, where a 
discussion of these models’ ability to simulate disease progression had already been 
undertaken and established. Due to the fact that the model was developed by using many 
of the structures of existing models, it is shown that in many cases the model reduces to 
and thus displays several of the desirable features of the existing models.  
 
As an initial test one can show that in the absence of any pathogens the model displays 
steady-state values for T cells and macrophages that are consistent with the Kirschner   
coinfection model of Section 7.1. This is done by noting that on inspection of            
eqns. (29a) – (29f) one recognises that in the uninfected state the model reduces to the 
uninfected state of the Kirschner model. The model dynamics for the uninfected state are 
displayed in Figures 21a and 21b. Similarly for the TB-infected state this new model also 
reduces to the Kirschner model. Model dynamics for the TB-infected state are shown in 
Figure 23.  
 
Moreover in the HIV-infected state eqns. (29a) – (29f) share similarities to the HIV 
model of Section 6.3.1. The difference between the two is that this new model has an 
added equation, eqn. (29d), used to represent infected macrophagic dynamics. Numerical 
simulation of the new model for Primary and asymptomatic HIV infection is shown        
in Figures 25.  
 
 
Modelling Coinfection Treatment 
 77 
8.2. Model Simulations  
 
8.2.1. Primary and Asymptomatic HIV Infection 
 
a. 












































































Figure 25: Simulations of the Primary and asymptomatic stage of HIV infection. The qualitative 




The numerical simulations shown in Figure 25, depicting primary and asymptomatic 
infection for the HIV infected state, show that the model is able to approximate virus 
dynamics according to what clinical records suggest (see Section 7.2.2.). One finds that 
the viral load does display the characteristic initial short-lived spike; thereafter it settles 
down to its steady-state value depicting the onset of the asymptomatic stage of infection. 
The T cell and infected T cell populations’ qualitative dynamics are also in good 
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agreement with what happens clinically in that during primary infection there is a dip in 
the T cell population and a spike in the infected T cell population. Thereafter the T cell 
population increases due to antigenic stimulation and the infected T cell population 
decreases due to specific immune responses and possible target cell limitation, 
whereupon they then settle down to their set-point values signalling the onset of the 
asymptomatic stage of infection.  
 
Furthermore examining the model quantitatively we have noted previously that according 




 virons per 
mm
3
 and the set-point value should settle in the range 10 – 100 virons per mm
3
. Figure 
25a shows that the simulation’s viral quantitative dynamics does also agree with these 
clinical observations.  
 
 
8.2.2. Complete Course of HIV Infection 
 
Since we have now established the model’s ability to simulate primary and asymptomatic 
stages of disease progression, one can test subsequent stages of disease progression. 
Typically after a few years of the asymptomatic stage of infection the immune system 
inevitably starts to collapse resulting in the onset of AIDS. The reasons for the immune 
system collapsing are not fully understood by immunologists; however, there is much 
ongoing biological research to determine the cause. Using the present model one can 
simulate the immune system collapse by assuming that the virion production rates of 
infected T cells ( VTg ) and macrophages ( Vg ) are increased over the period of a           
year [76]. This could be caused by mutations, increased efficiency in virion production or 
the immune system’s inability to contain virion production any longer due to, for 
example, large numbers of latently infected cells becoming active. 
 
The complete course of HIV infection is shown in Figure 26. After an asymptomatic 
period of a few years, in this case five years into the infection, the viral production rate of 
both infected T cells and macrophages are simultaneously increased over the following 
year. This simulates the immune system collapsing, thereby signalling the onset of AIDS. 








 year) onward. 




 year) both the T cell count and macrophage 
population are descending steeply while the viral load experiences a similarly dramatic 
ascent. These dynamics, as displayed by the model, are typical of the generalised clinical 
observations of the HIV disease progressing towards AIDS with the eventual collapse of 
















































































Figure 26: Simulations of the complete course of HIV infection. By the 5
th
 year the immune 
system begins to display signs of collapsing, thus signaling the onset of AIDS. Towards the end 
of the 6
th
 year the immune system is almost totally eroded resulting in full-blown AIDS and 
possibly even death.  
 
 




8.2.3. HIV-TB Coinfection 
 
a. 






















































































Figure 27: Simulations of the HIV-TB coinfection. The model is able to demonstrate that HIV-
TB coinfection results in a higher set-point viral load when compared to HIV infection alone.   
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It has been noted earlier that an HIV-TB coinfected individual is more likely to progress 
rapidly toward AIDS than the person who has HIV alone. One of the factors that are 
indicative of rapid disease progression is the viral load. In general a higher viral load 
correlates with an increased likelihood of rapidly progressing towards AIDS. One way to 
test the model’s ability to display realistic clinical characteristics is to test whether TB 
infection in an HIV-positive individual does indeed increase the viral load which would 
thereby cause the immune system to collapse in a shorter amount of time.  
 
Figure 27 simulates HIV-TB coinfection by introducing TB into the system on the 1000
th
 
day, about two and three quarter years, into HIV infection. Figures 27a and 27b show that 
coinfection results in an associated increase in viral load. The set-point viral load for HIV 
alone is about 282 virions per mm
3
. This is compared to 341 virions per mm
3
 for HIV-TB 
coinfection, which represents an increase of 25% in the viral load of the coinfected 
individual over the HIV-infected individual. The coinfected individual’s higher viral load 
would normally result in the immune system collapsing in a shorter amount of time. As 
has been discussed in Section 7.2.4, the higher viral load is due to the fact that there are 
more susceptible cells (macrophages and T cells) for HIV virions to infect. Figures 27c 
and 27d show that T cell and macrophage populations are slightly higher for HIV-TB 
coinfection than for HIV infection alone. This is as expected since the introduction of 
another pathogen, TB, into the system stimulates T cells and macrophages to increase 
their numbers in order to fight off the additional diseases. However, the already 
overworked immune system struggles to keep TB in check. From figure 27e one finds 
that the bacterial levels rapidly increase before settling to its set-point value establishing 
chronic TB infection.  
 
 
8.3. Modelling Treatment 
 
Having evaluated the model to ensure that it simulates the dynamics of HIV-TB            
coinfection in a realistic manner, we are now able to tackle the fundamental reason for 
building the HIV-TB coinfection model, which is to use the model to test the different 
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treatment strategies for coinfection. We add treatment mechanisms to the coinfection 
model, eqns (29a) – (29f), in the following way.  
 
We firstly consider the treatment of HIV. One recalls that HIV chemotherapy uses 
protease and reverse transcriptase inhibitors. Protease inhibitors cause the formation of 
noninfectious virions. Consequently eqn. (29e), which models the HIV virions 
population, is divided by the therapeutic action of protease inhibition into two 
subpopulations. These subpopulations are the infectious HIV virions ( iV ), and the non-
infectious HIV virions ( niV ), where the total virion population is given by nii VVV . 
The action of protease inhibitors is modelled by including )1( PI  in front of the 
infectious HIV virions source terms, and PI  in front of the noninfectious HIV virions 
source terms. PI  ranges from 0 to 1 with 1PI  simulating a 100% effective protease 
inhibitor. 
 
The second class of anti-HIV drugs, reverse transcriptase inhibitors, inhibits the HIV 
virion’s ability to infect successfully immune system cells such as T cells and 
macrophages. Thus the HIV infection terms of eqn. (29) for macrophages and T cells, 
)()( tVtTkV and )()(2 tVtMk  respectively, are modified by appending )1( RT  in front. 
RT  ranges from 0 to 1 with 1RT  simulating a 100% effective protease inhibitor. 
 
Now turning our attention to the anti-TB drugs we recall that their therapeutic 
mechanisms of action were their bacteriostatic and bactericidal action. Bacteriostatic 
drugs inhibit the growth of the bacterial population and are therefore modelled by 
including )1( TB  in front of the logistic growth term of eqn. (29f). TB  ranges from 0  
to 1 with 1TB  simulating a 100% effective growth inhibitor. Bactericidal drugs 
actively kill the bacterial population and are therefore modelled by appending TB  to the 
bacterial death term of eqn. (29f), where 1TB . 1TB  has a 0% efficacy, but this 
increases as TB  is increased. 
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Applying the antiretroviral and TB-dug therapeutic mechanisms to eqn. (29) yields a new 
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We can now use this model to test the different coinfection treatment scenarios for 
treating HIV-TB coinfected individuals. Initially we test simultaneous treatment of HIV 
and TB. We then simulate treating for TB first and once that is completed treating for 
HIV. By using the TB first HIV second treatment strategy there are two different 
scenarios that can be tested, these are: the commencement of treatment early on during 
the immune system collapse and the commencement of treatment late into the immune 
system collapse. Such a simulation is relevant since some individuals would be able to 
commence treatment early due to already having been diagnosed HIV-positive before the 
symptomatic stages of HIV disease progression. Treatment can typically begin with the 
first signs of an AIDS-related complex such as TB. Others, mainly in developing 
countries, are not aware of their HIV status until late into their immune system collapse. 
Thus treatment commences much later. Concluding the simulations for HIV-TB 
treatment, the final simulation that is tested treats HIV first and then TB. This treatment 
strategy is not practical (see section 8.3.4.), but is included to demonstrate the ability of 
mathematical models to test situations that would otherwise not be feasible.  
 
 
8.3.1. Simultaneous HIV-TB Treatment 
 
Having already pointed out that treating HIV and TB simultaneously is generally not 
recommended, we note that the simulations for concurrent treatment shown in Figure 28 
considers only the levels of the various populations that constitute the immune system-
HIV-TB model and does not take into account adverse side-effects or drug-drug 
interactions.  
 
On inspecting the simulations for the simultaneous treatment of HIV and TB shown in 
Figure 28 one finds that, when both drug regimes are administered concurrently, the best 
results in terms of decreasing viral and bacterial loads and increasing immune system 
cells are obtained, as compared to treating TB then HIV shown in Figures 30 and 31 
respectively. 
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Figure 28: Simulations of the simultaneous treatment of HIV and TB. The viral load is brought 
down to undetectable levels by the 27
th
 week of treatment; nevertheless, HIV treatment 
has to be continued indefinitely. The TB treatment course lasts 6 months by which time 
TB infection is eliminated from the system.  
 
 
In Figure 28a the antiretroviral treatment commences on day 2112 when the viral load is 
2961 virions per mm
3
 and decreases the viral load to undetectable levels (< 0.05 virions 
per mm
3
) by day 2301. This represents a time frame of 27 weeks. Current guidelines for 
antiretroviral therapy suggest that viral load should be brought down to undetectable 
levels by between 16–24 weeks [109]. Thus the simulations time frame of 27 weeks is 
realistic especially when considering that initially the individual was HIV-TB coinfected 
and had a high viral load. 
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On examining Figure 28d one finds that as a result of TB treatment the TB bacteria are 
decreased to levels very close to zero in a short space of time. Thus one might be tempted 
to cease TB treatment as soon as this happens. In practice TB treatment is carried out for 
180 days so as to ensure all traces of the bacteria, no matter how minute, are killed. As an 
example one sees from the simulation of the premature cessation of TB treatment shown 
in figure 29 that even when the TB bacterial population is reduced to almost zero and TB 
treatment is stopped, an almost instant rebound in the bacterial population does occur. 
Therefore it is necessary to complete the entire 180 days of the anti-TB drug course.  
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Figure 29: Simulation of premature cessation of TB treatment. One finds that TB treatment 
rapidly brings the bacterial levels close to zero; however, if treatment is stopped prematurely, a 
rebound in the TB infection occurs just as rapidly. 
 
 
8.3.2. Treating TB then HIV: Advanced Stages of Immune Collapse  
 
When treating coinfected individuals most medical practitioners recommend treating for 
TB first and then HIV so as to minimise the compounded side effects and drug-drug 
interactions between the antiretroviral and antibacterial drugs. Figures 27a and 27b show 
that, when TB is introduced into the body, the HIV viral load increases. One can now use 
the model to test if the converse is true, that is, by treating TB does the HIV viral load 
decrease? If this be the case, it might not be necessary to treat both HIV and TB 
simultaneously, thus sparing the coinfected individual from any compounded side effects 
and drug-drug interactions that might result from simultaneous treatment. 
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Figure 30: Simulations of treating TB then HIV at advanced stages of immune system collapse. 
One finds that treating TB first does indeed decrease the viral load and halts T cell decline. 
However, since treatment started late into the immune system collapse, this might not be enough 
to ensure the coinfected individual’s survival.  
 
 
Figure 30 shows simulations of treating of TB then HIV, where treatment is commenced 
at advanced stages into the immune system collapse when the T cell count is 72 T cells 
per mm
3
 and the viral load is 4005 virions per mm
3
. One finds that treating TB does 
indeed decrease the viral load. The viral load decreases from about 4005 to 2897 virions 
per mm
3
. Moreover Figure 30b shows (red portion of graph where there is a flat plateau) 
that the T cell population halts its decline and stabilises during TB treatment. 
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Nevertheless the TB drugs do not help to increase significantly the T cell count. The 
patient is left with a T cell count of around 77 T cells per mm
3 
after TB treatment where 
the pretreatment level was 72 T cells per mm
3
. A viral load of 2897 per mm
3
 and a T cell 
count of 77 per mm
3
 are indeed dangerous and could result in death. Here the TB drugs 
alone are not enough to ensure the patient’s survival and in this case the medical 
practitioner might have no choice but to treat for both diseases, complications resulting 
from simultaneous treatment notwithstanding.  
 
In Figure 30 treatment was only commenced very late into the immune system collapse. 
Nevertheless we have seen that TB treatment does decrease the viral load as well as 
stabilise the T cell count, thus preventing it from falling any further. One might 
hypothesise that, if we treat TB early in the immune system collapse, for example, when 
the T cell count just dips under 200 per mm
3
, it might not be necessary to treat for both 
diseases, thereby avoiding any complication arising from simultaneous treatment. We test 
this hypothesis in the simulations shown in Figure 31.  
 
 
8.3.3. Treating TB then HIV: Early Stages of Immune Collapse  
 
Figure 31 shows the results of simulating the commencement of TB treatment during 
early stages in the immune system collapse. Viral load and T cell count at the beginning 
of TB treatment are 1935 virions and 198 T cells per mm
3
 respectively. Figure 31b shows 
that, when TB is treated early on during the immune system collapse, in this case when 
the   T cell count dips just below 200 per mm
3
, the TB treatment is able to halt the T cell 
decline and stabilise the T cell level (red portion of Figure 31b where there is a flat 
plateau) at 198 T cells per mm
3
 by the end of the TB treatment period. A similar situation 
is observed for the viral load shown in Figure 31a. Here the TB treatment results in 
stabilising the viral load and keeping it relatively steady at about 1137 virions per mm
3
. A 
viral load of 1137 virions per mm
3
 and a T cell count of 198 per mm
3
 are much safer 
levels compared to those observed in the treatment of TB at advanced stages of the 
immune system collapse, which were 2897 virions per mm
3
 and 77 T cells per mm
3
 
respectively. A comparison of the early versus late commencement of TB treatment 
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shows that the late treatment has an associated viral load that is approximately 60.8% 
greater than early treatment and a T cell count that is about 61.1% less than early 
treatment. Consequently, if the patient is in the early stages of the immune system 
collapsing, medical practitioners might deem it unnecessary to expose patients to 
complications arising from treating both HIV and TB simultaneously and treat only      
for TB.  
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Figure 31: Simulations of treating TB then HIV at early stages of immune system collapse. By 
treating TB at early stages of the immune system collapse, one is able to halt the decline in T cells 
and lower the viral load to acceptable levels so that concurrent HIV-TB treatment would not be 
necessary. 
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8.3.4. Treating HIV then TB  
 
An interesting simulation that can be performed is treating HIV first and then TB. Such 
experiments show the utility of developing mathematical models, which allows us the 
opportunity to experiment with simulations that are not clinically practical. All 
simulations so far have treated TB first as this is the method utilised by CAPRISA to run 
their START trials. CAPRISA adopts this method for the following reason. One might 
hypothesise that by treating HIV first the immune system might recover sufficiently to 
hold off the possible danger that TB poses to the coinfected individual; however, once 
HIV treatment has commenced one cannot suspend the treatment of HIV to treat TB 
since this might promote the evolution of mutant strains of HIV. This would serve only to 
further jeopardise the coinfected individual. Thus, if one commences by treating for HIV 
first, one has to treat for TB while treating for HIV and would therefore still be faced 
with the compounded side effects and drug-drug interactions of combining HIV and TB 
treatment. The only realistic hope one has of negating the possibility of simultaneous 
treatment is to treat for TB first. Nevertheless, even though treating HIV first is not 
practical in a clinical setting, by using the model one can simulate this treatment strategy.   
 
Simulations of the treatment of HIV in an HIV-TB coinfected individual are shown in 
Figure 32. One observes in Figure 32a that when antiretroviral treatment is initiated on 
day 2112 the viral load is decreased to below 0.05 virions per mm
3
 by day 2298. From 
Figures 32b and 32c one finds that by the 2298
th
 day the T cell count and macrophage 
population recover substantially and the individual reverts once more to the 
asymptomatic stage of disease progression. Figure 32d shows that the immune system is 
again able to suppress the M. tuberculosis population and keep it at a low level. 
 
From the dynamics observed in Figure 32 one sees that treating HIV first in an HIV-TB          
coinfected individual could be a very desirable strategy. With new HIV drugs in the 
developmental phase that target different treatment mechanisms than the ones being 
currently used there might just be some hope of implementing this treatment strategy 
since one might treat HIV initially with one class of HIV drugs, then treat TB and          
… 
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thereafter treat HIV once again with a different class of HIV drugs. By using the different 
classes of HIV drugs before and after TB treatment one could possibly reduce the risk of 
HIV-drug resistance.  
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Figure 32: Simulations of treating HIV in an HIV-TB coinfected individual. By treating HIV first 
one is able to bring down the viral load and allow immune reconstitution to take place. Once the 











Medical practitioners are often faced with the question, when should one treat for TB in 
HIV coinfected individuals? The significance of this question is great enough to warrant 
medical trials in attempting to answer it. As we have noted, HIV-TB coinfection poses a 
considerable problem in Sub-Saharan Africa. It is therefore of utmost importance that we 
understand the dynamics involving the treatment of HIV-TB coinfection. 
 
Bearing these facts in mind this dissertation was undertaken. After a review of the 
scientific literature many examples of HIV models were found, several of these models 
also included treatment mechanisms for anti-HIV drugs. However, with regards to 
mathematical models of HIV-TB coinfection only one model was found even though 
coinfection is endemic in Sub-Saharan Africa. This model did not include any treatment 
mechanisms for HIV or TB, but did offer a framework on which a model with treatment 
mechanisms could be built. 
 
In order to facilitate mechanisms for anti-HIV treatment into the model, one was able to 
draw on the large array of existing HIV treatment models. Since no treatment models for 
TB could be found, one had to model TB treatment according to the known mechanisms 
of interaction of anti-TB drugs. The challenge that lay ahead was manipulating all these 
separate constituent elements to develop an HIV-TB coinfection model which included 
treatment mechanisms for both diseases. Once this had been achieved one was then in a 
unique position to be able to offer insights and predictions purely from simulations into 
the different treatment strategies used to treat coinfection. Although clinical trials 
rightfully are at the core of medical research of this nature, model simulations do offer 
certain advantages. Model simulations are far less time intensive and require fewer 




The dissertation culminated with the development of a coinfection model with treatment 
mechanisms, which was presented in Chapter 8. One could now test the different 
scenarios of coinfection treatment and offer some suggestions for optimising treatment 
strategies. The model simulations of Section 8.3.2. demonstrated that, if one treats     
HIV-TB co-infection at advanced stages of the immune system collapsing towards AIDS, 
treating initially for TB alone might not be enough to allow sufficient immune 
reconstitution to ensure the individual’s survival. In this case it might be necessary to 
simultaneously treat for both diseases even though the combination of the two drug 
regimes might have undesirable consequences. Nevertheless the model simulations of 
Section 8.3.3. show that there are situations when the simultaneous treatment of 
coinfection might not be necessary. These simulations revealed that if an individual is      
co-infected during relatively early stages of the immune system collapsing one might 
treat for TB alone before treating for HIV. In addition there were other useful features 
that the model was able to demonstrate, for example, the model showed in Section 8.3.2. 
that, if TB treatment is not carried out for the complete six month course, TB infection 
can rebound even if the infection seems to be cleared when the individual ceases 
treatment. Model simulation of Section 8.3.4. showed that, if one could treat for HIV first 
without treating for TB, the immune system would recover sufficiently to allow the 
coinfected individual the opportunity to stop HIV treatment and treat for TB alone. 
However, after TB treatment is completed and HIV treatment is started once again, the 
emergence of resistance to anti-HIV drugs could worsen the individual’s prognosis. 
Nevertheless a possible solution to this problem was offered in that one could use 
different types (having different therapeutic mechanisms) of anti-HIV drugs before and 
after TB treatment.    
 
The results above serve to illustrate that mathematical models are useful tools when 
applied to medical and biological settings. Previously it was through the use of a 
mathematical model in HIV/AIDS research that a major breakthrough in understanding 
the dynamics of the disease during the latent stage of infection was achieved. Contrary to 
popular belief at the time the model was able to counter-intuitively demonstrate that viral 
dynamics are not static during asymptomatic stage of infection. In fact HIV virions are 
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being produced and cleared at the astonishing rate of 10 billion virions per day. Similarly 
the model that was developed during this dissertation was able to offer some useful 
insights even if they were very much in keeping with what one would intuitively expect. 
Since the model was built from known biological interactions, results that reinforce one’s 
intuition do serve the purpose of enhancing one’s confidence of its validity.  
 
Mathematical modelling offers a rigorous method of building a conceptual framework 
when attempting to understand the dynamics of a disease. Clearly there is a great need for 
the interdisciplinary collaboration between mathematicians, immunologists and even 
computational scientists. As a result of the staggering infection rates and numbers of 
people who have been previously infected with HIV, there is a lot of quantitative data 
that has been amassed over the years. This data can be used to calibrate model parameters 
and test model hypotheses. These models can in turn be used to make predictions for 
disease progression and improve our understanding of disease dynamics. Disease 
modelling is currently a very active field of research with many interesting and 
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